<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Levetiracetam: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Levetiracetam: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Levetiracetam: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9904" href="/d/html/9904.html" rel="external">see "Levetiracetam: Drug information"</a> and <a class="drug drug_patient" data-topicid="10798" href="/d/html/10798.html" rel="external">see "Levetiracetam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58883358"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Levetiracetam Safety Alert</span>
<span class="collapsible-date">November 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has issued a drug safety communication warning that levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) can cause Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a rare but serious hypersensitivity reaction that can be life-threatening if not diagnosed and treated quickly. The onset of DRESS typically occurs 2 to 8 weeks after starting levetiracetam; symptoms may include rash, fever, or swollen lymph nodes but can quickly progress, resulting in injury to organs including the liver, kidney, lungs, heart, or pancreas, the need for hospitalization, and death. The FDA is requiring warnings about this risk to be added to the prescribing information and Medication Guide. Health care providers should advise patients of the signs and symptoms of DRESS and to stop taking their medication and seek immediate medical attention if DRESS is suspected during treatment with levetiracetam.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr&amp;token=S5wPp1ALA0YTRjCgLUvI11sJI393GqdX%2Bap2fnqG8KapSufGT7LOdLVONldFGttP0u5iNiN6%2FTBUNgS2dNMugMqG%2BB%2FENIS9dWpBIob0s3uhJ382laiLM7VCaRgnOzm4PILMYe%2FPZmL2wP7UX%2B5fmHrrfn5sx7lKxgQgMXQRIw8%3D&amp;TOPIC_ID=12910" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr</a></p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187641"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elepsia XR;</li>
<li>Keppra;</li>
<li>Keppra XR;</li>
<li>Roweepra;</li>
<li>Roweepra XR [DSC];</li>
<li>Spritam</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867349"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Levetiracetam;</li>
<li>AG-Levetiracetam;</li>
<li>APO-Levetiracetam;</li>
<li>Auro-Levetiracetam;</li>
<li>BIO-Levetiracetam [DSC];</li>
<li>JAMP-Levetiracetam;</li>
<li>Keppra;</li>
<li>M-Levetiracetam;</li>
<li>MINT-Levetiracetam;</li>
<li>NAT-Levetiracetam;</li>
<li>NRA-Levetiracetam;</li>
<li>PDP-Levetiracetam;</li>
<li>PMS-Levetiracetam;</li>
<li>Priva-Levetiracetam [DSC];</li>
<li>PRO-Levetiracetam-250;</li>
<li>PRO-Levetiracetam-500;</li>
<li>PRO-Levetiracetam-750;</li>
<li>RAN-Levetiracetam [DSC];</li>
<li>RIVA-Levetiracetam;</li>
<li>SANDOZ Levetiracetam;</li>
<li>TEVA-Levetiracetam</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2875435"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span></li></ul></div>
<div class="block don drugH1Div" id="F53462489"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Transition IV therapy to oral when able; when switching from oral to IV formulation, the total daily dose (individual dose and frequency) should be equivalent (manufacturer's labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="434e0708-9b3e-4d5c-b567-50ff276aa5da">Neonatal seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal seizures: </b>Limited data available; optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Loading dose:</i> IV: 20 to 60 mg/kg as a single dose; if seizures not controlled or recur within 15 minutes, a repeat dose of 20 to 50 mg/kg may be given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31477643','lexi-content-ref-29636029','lexi-content-ref-34750046','lexi-content-ref-35350164','lexi-content-ref-21397167','lexi-content-ref-22495532','lexi-content-ref-32162678','lexi-content-ref-35311411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31477643','lexi-content-ref-29636029','lexi-content-ref-34750046','lexi-content-ref-35350164','lexi-content-ref-21397167','lexi-content-ref-22495532','lexi-content-ref-32162678','lexi-content-ref-35311411'])">Ref</a></span>); cumulative loading doses have been reported to range from 20 to 150 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27872177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27872177'])">Ref</a></span>). Loading doses on the higher end (eg, 60 mg/kg) may be more effective than lower doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32385134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32385134'])">Ref</a></span>). Higher cumulative loading doses were reported in patients on extracorporeal membrane oxygenation (ECMO) following congenital heart disease repair (48 to 80 mg/kg) compared to non-ECMO patients (20 to 40 mg/kg); for patients requiring ECMO, seizure burden was unchanged with levetiracetam and all required treatment with multiple antiepileptic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35350164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35350164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance dose:</i> IV: Initial: 20 to 60 mg/kg/day divided twice daily; dividing dose 3 times daily has also been reported. Doses may be increased by 10 to 20 mg/kg/day based on clinical response; reported range is highly variable and includes doses up to 120 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28553374','lexi-content-ref-31477643','lexi-content-ref-29636029','lexi-content-ref-32950862','lexi-content-ref-34750046','lexi-content-ref-21397167','lexi-content-ref-23921284','lexi-content-ref-30296665','lexi-content-ref-32385134','lexi-content-ref-27872177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28553374','lexi-content-ref-31477643','lexi-content-ref-29636029','lexi-content-ref-32950862','lexi-content-ref-34750046','lexi-content-ref-21397167','lexi-content-ref-23921284','lexi-content-ref-30296665','lexi-content-ref-32385134','lexi-content-ref-27872177'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral (<i>immediate release: Oral solution</i>): Initial: 10 to 30 mg/kg/day divided twice daily; higher initial doses up to 60 mg/kg/day in 2 to 3 divided doses have also been reported. Doses may be increased by 10 to 20 mg/kg/day increments based on clinical response; reported doses are variable and range from 8 to 120 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20133173','lexi-content-ref-32950862','lexi-content-ref-34750046','lexi-content-ref-21094062','lexi-content-ref-17608315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20133173','lexi-content-ref-32950862','lexi-content-ref-34750046','lexi-content-ref-21094062','lexi-content-ref-17608315'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F187656"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Avoid abrupt discontinuation of therapy to reduce risk of increased seizure frequency or status epilepticus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Use oral solution in infants and children ≤20 kg. Parenteral IV therapy should be temporary and transitioned to oral when able; when switching from oral to IV formulation, the total daily dose (individual dose and frequency) should be the same.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="253b2702-f6d0-4326-b9c6-fd727bf571ff">Myoclonic seizures with juvenile myoclonic epilepsy; adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myoclonic seizures with juvenile myoclonic epilepsy; adjunct:</b> Children ≥12 years and Adolescents: IV, Oral <i>(immediate release: Tablets, oral solution [eg, Keppra], or tablets for oral suspension [Spritam])</i>: Initial 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily based on response and tolerability to the recommended dose of 1,500 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6812a6bc-9d43-4051-8f22-ce225deac916">Partial-onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Partial-onset (focal) seizures: Note:</b> Dosing for monotherapy or adjunct therapy is the same for indicated oral preparations.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to &lt;6 months: IV, Oral <i>(immediate release: Oral solution [monotherapy or adjunct])</i>: Initial: 7 mg/kg/dose twice daily; increase dosage every 2 weeks by 7 mg/kg/dose twice daily based on response and tolerability to the recommended dose of 21 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;4 years: IV, Oral <i>(immediate release: Oral solution or tablets [monotherapy or adjunct])</i>: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily based on response and tolerability to the recommended dose of 25 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents &lt;16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Monotherapy or adjunct: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily based on response and tolerability to the recommended dose of 30 mg/kg/dose twice daily; the maximum daily dose was 3,000 mg/<b>day</b> in clinical trials.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: Monotherapy or adjunct:</p>
<p style="text-indent:-2em;margin-left:10em;">Weight-directed dosing: <i>Oral solution</i>: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily based on response and tolerability to the recommended dose of 30 mg/kg/dose twice daily; the maximum daily dose was 3,000 mg/<b>day</b> in clinical trials.</p>
<p style="text-indent:-2em;margin-left:10em;">Fixed dosing: <i>Tablet (immediate release [eg, Keppra] or for oral suspension [Spritam])</i>:</p>
<p style="text-indent:-2em;margin-left:12em;">20 to 40 kg: Initial: 250 mg twice daily; increase dosage every 2 weeks by 250 mg twice daily based on response and tolerability to the maximum recommended dose of 750 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;40 kg: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg twice daily based on response and tolerability to the maximum recommended dose of 1,500 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release<i> (eg, Elepsia XR [adjunct]; Keppra XR [monotherapy or adjunct])</i>: Children ≥12 years and Adolescents: Initial: 1,000 mg once daily; may increase dosage every 2 weeks by 1,000 mg/day based on response and tolerability to a maximum recommended dose of 3,000 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Monotherapy or adjunct: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily based on response and tolerability to a maximum recommended dose of 1,500 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release <i>(tablets, oral solution [eg, Keppra], tablets for oral suspension [Spritam]; monotherapy or adjunct)</i>: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg twice daily based on response and tolerability to the maximum recommended dose of 1,500 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release <i>(eg, Elepsia XR [adjunct], Keppra XR [monotherapy or adjunct])</i>: Initial: 1,000 mg once daily; increase dosage every 2 weeks by 1,000 mg/day based on response and tolerability to a maximum recommended dose of 3,000 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f634a32-a94f-46b6-8ab0-20208300256c">Seizure prophylaxis, traumatic brain injury</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure prophylaxis, traumatic brain injury: Note:</b> Current guidelines state that there is not sufficient evidence to recommend levetiracetam over phenytoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30829890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30829890'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available, optimal dose not defined: IV, Oral (<i>tablets, oral solution [eg, Keppra]</i>): 20 to 55 mg/kg/day in divided doses twice daily; reported range: 5 to 55 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26669640','lexi-content-ref-23876024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26669640','lexi-content-ref-23876024'])">Ref</a></span>). In one prospective observational study, patients with moderate to severe traumatic brain injury (TBI) (n=34, ages 5 days to 16 years) received a median dose of 20 mg/kg/day in divided doses twice daily (range: 5 to 40 mg/kg/day). 17.6% patients experienced seizure despite therapy, with the highest percentage in younger patients and those with a history of abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26669640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26669640'])">Ref</a></span>). Another prospective observational study of patients with TBI at risk for seizures used a dose of 55 mg/kg/day in divided doses (n=20, ages 6 to 17 years); one patient developed seizures 7 days after initial trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23876024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23876024'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7a80799-b46d-4061-b569-fd59d98f53e5">Status epilepticus, urgent therapy/second-phase therapy or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus, urgent therapy/second-phase therapy or refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>American epilepsy society guidelines</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382'])">Ref</a></span>): Limited data available: Infants, Children, and Adolescents: IV: 60 mg/kg as a single dose; maximum dose: 4,500 mg/dose; initiate maintenance therapy based upon clinical response and type of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurocritical care guidelines </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>): Limited data available: Infants, Children, and Adolescents: IV: 20 to 60 mg/kg as a single dose; initiate maintenance therapy based upon clinical response and type of seizure disorder; <b>Note:</b> Maximum dose in adults is 3,000 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f1712ee-157a-43be-a862-1561e9410163">Tonic-clonic seizures; primary generalized; adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tonic-clonic seizures; primary generalized; adjunct:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily based on response and tolerability to the recommended dose of 30 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed: <i>Oral solution or tablets:</i> Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily based on response and tolerability to the recommended dose of 30 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed-dosing: <i>Orally disintegrating tablets [Spritam]:</i></p>
<p style="text-indent:-2em;margin-left:10em;">20 to 40 kg: Initial: 250 mg twice daily; increase dosage every 2 weeks by 250 mg twice daily based on response and tolerability to the maximum recommended dose of 750 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;40 kg: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg twice daily based on response and tolerability to the maximum recommended dose of 1,500 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: IV, Oral <i>(immediate release: Oral solution or tablets [eg, Keppra], tablets for oral suspension [Spritam]):</i> Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily based on response and tolerability to the recommended dose of 1,500 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117835"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV, Oral <i>(immediate-release formulations [tablets, oral solution] and tablets for oral suspension)</i>: Infants, Children, and Adolescents: GFR &lt;50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral extended-release formulations (<i>Elepsia XR, Keppra XR</i>): Children ≥12 years and Adolescents: There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (CrCl &gt;130 mL/minute/1.73 m<sup>2</sup>):</b> There are no pediatric-specific recommendations for dosing in patients with augmented renal clearance; based on adult pharmacokinetic studies, dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Dialyzable (50%):</p>
<p style="text-indent:-2em;margin-left:4em;">IV, Oral <i>(immediate-release formulations [tablets, oral solution] and tablets for oral suspension)</i>: Infants, Children, and Adolescents: Administer 50% of normal dose every 24 hours; a supplemental dose after hemodialysis is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral extended-release formulations (<i>Elepsia XR, Keppra XR</i>): Children ≥12 years and Adolescents: There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">IV, Oral <i>(immediate-release formulations [tablets, oral solution] and tablets for oral suspension)</i>: Infants, Children, and Adolescents: Administer 50% of the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral extended-release formulations (<i>Elepsia XR, Keppra XR</i>): Children ≥12 years and Adolescents: There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous renal replacement therapy (CRRT):</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV, Oral <i>(immediate-release formulations [tablets, oral solution] and tablets for oral suspension)</i>: Infants, Children, and Adolescents: Administer 50% of the dose; monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of patient response and adverse reactions is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration): </b>There are no pediatric-specific recommendations provided in the manufacturer's labeling. Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Based on adult experience, dose adjustment may be necessary, and close monitoring of patient response and adverse reactions is recommended.</p></div>
<div class="block dohp drugH1Div" id="F51117836"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary</p></div>
<div class="block doa drugH1Div" id="F187644"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9904" href="/d/html/9904.html" rel="external">see "Levetiracetam: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> When switching between oral and IV formulations, the total daily dose should be the same.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbff5dc3-90c8-4af2-b773-f6bf7f5b614d">Craniotomy, seizure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">Craniotomy, seizure prophylaxis (off-label use):</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>IV</b>: 500 mg to 1 g intraoperatively prior to incision (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Paisansathan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Paisansathan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: <b>IV, Oral:</b> 1 g/day in 2 divided doses; usual dosage range: 500 mg to 3 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37123333','lexi-content-ref-22738092','lexi-content-ref-26945547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37123333','lexi-content-ref-22738092','lexi-content-ref-26945547'])">Ref</a></span>); adjust dose based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22738092','lexi-content-ref-25511789','lexi-content-ref-26945547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22738092','lexi-content-ref-25511789','lexi-content-ref-26945547'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67e732c4-b7e3-4abd-be74-0e133a5b58d8">Focal onset seizures and generalized onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal (partial) onset seizures and generalized onset seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> FDA approved for mono- and adjunctive therapy of focal (partial) onset seizures, and adjunctive therapy of juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures; used off label for other seizure types (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29898971','lexi-content-ref-17283312','lexi-content-ref-22933814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29898971','lexi-content-ref-17283312','lexi-content-ref-22933814'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose based on response and tolerability to the maximum recommended dose of 1.5 g twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release (FDA approved only for focal [partial] onset seizures): Initial: 1 g once daily; increase every 2 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients with epilepsy, oral loading doses of 1.5 to 2 g (immediate release) have been well tolerated and may be useful for more rapidly achieving steady-state serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10845730','lexi-content-ref-18505995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10845730','lexi-content-ref-18505995'])">Ref</a></span>); however, the necessity of an oral loading dose has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose based on response and tolerability to a maximum of 1.5 g twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Additional benefit of oral or IV doses &gt;3 g/day has not been established; however, oral doses of 4 g/day have been studied in patients with refractory epilepsy but may be associated with a greater incidence of somnolence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10845730','lexi-content-ref-16078205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10845730','lexi-content-ref-16078205'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus (off-label use):</b>
<b>IV:</b> 1 to 3 g as a single dose administered at a rate of 2 to 5 mg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>) or 40 to 60 mg/kg as a single dose infused over 5 to 15 minutes in combination with a parenteral benzodiazepine. Maximum single dose: 4.5 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17442002','lexi-content-ref-Drislane.2018','lexi-content-ref-Jirsch.2020','lexi-content-ref-31774955','lexi-content-ref-19264738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17442002','lexi-content-ref-Drislane.2018','lexi-content-ref-Jirsch.2020','lexi-content-ref-31774955','lexi-content-ref-19264738'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bb43b5d-eafa-4e3a-b573-f25cb6d2da10">Subarachnoid hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subarachnoid hemorrhage (short-term seizure prophylaxis) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Consider use in patients with seizure at presentation (onset seizure) or patients at high risk for seizures (eg, those with ruptured middle cerebral artery aneurysm, high-grade aneurysmal subarachnoid hemorrhage, intracranial hemorrhage, hydrocephalus, cortical infarction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37212182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37212182'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: <b>IV:</b> 20 mg/kg (rounded to the nearest 250 mg) as a one-time dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19898966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19898966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: <b>IV:</b> 1 g every 12 hours for up to 7 days; may be increased to a maximum dose of 1.5 g every 12 hours if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37212182','lexi-content-ref-19898966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37212182','lexi-content-ref-19898966'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f970798-6260-4e76-a464-e73e2e2b6d2f">Traumatic brain injury</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Traumatic brain injury (severe acute</b>
<b>) (short-term seizure prophylaxis) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: <b>IV:</b> 20 mg/kg (rounded to the nearest 250 mg) as a one-time dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19898966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19898966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: <b>IV: </b>1 g every 12 hours for 7 days; may be increased to a maximum dose of 1.5 g every 12 hours if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19898966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19898966'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion between oral levetiracetam IR and ER dosage forms</i>: When switching between ER and IR formulations of levetiracetam, the same total daily dose should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19317886','lexi-content-ref-19264451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19317886','lexi-content-ref-19264451'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>In chronic therapy, withdraw gradually to minimize the potential of increased seizure frequency and status epilepticus, unless safety concerns require a more rapid withdrawal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991779"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note: </b>Loading doses should be utilized when indicated (see adult dosing) and administered unadjusted for renal function or dialytic therapy. For maintenance doses, the risks/benefits favor dosing on the higher side of the recommended dosing range when initiating treatment, particularly in patients with acute seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The manufacturer's labeling recommends estimating CrCl using the Cockcroft-Gault formula adjusted for BSA as follows: CrCl (mL/minute/1.73 m<sup>2</sup>) = CrCl (mL/minute)/BSA (m<sup>2</sup>) x 1.73.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IR and IV formulations</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25929593','lexi-content-ref-25312351','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25929593','lexi-content-ref-25312351','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 80 to 130 mL/minute/1.73 m<sup>2</sup>: 500 mg to 1.5 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to &lt;80 mL/minute/1.73 m<sup>2</sup>: 500 mg to 1 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;50 mL/minute/1.73 m<sup>2</sup>: 250 to 750 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: 250 to 500 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>: 250 to 500 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER tablet:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;80 mL/minute/1.73 m<sup>2</sup>: 1 to 3 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 80 mL/minute/1.73 m<sup>2</sup>: 1 to 2 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 500 mg to 1.5 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 500 mg to 1 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma (eg, traumatic brain injury) or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to confirm presence of ARC in these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Doses derived from pharmacokinetic simulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32113977','lexi-content-ref-21950640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32113977','lexi-content-ref-21950640'])">Ref</a></span>) and expert opinion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IR and IV</i> formulations: CrCl &gt;130 mL/minute/1.73 m<sup>2</sup>: 1.5 to 2 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER tablet:</i> CrCl &gt;130 mL/minute/1.73 m<sup>2</sup>: 3 to 4 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50%):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IR and IV formulations: </i>500 mg to 1 g every 24 hours; a supplemental dose of 250 to 500 mg is recommended post each hemodialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25929593','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25929593','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER tablet: </i>Use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: Note:</b> Limited data available; dosing based on a case report demonstrating toxicity at a higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24739070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24739070'])">Ref</a></span>) and expert opinion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IR and IV formulations</i>: 250 to 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER tablet: </i>Use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations assume high-flux dialyzers and flow rates of ~1,500 to 3,000 mL/hour, unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: <b>Note:</b> Dose based on limited data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33217623','lexi-content-ref-32223067','lexi-content-ref-27546759','lexi-content-ref-28446744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33217623','lexi-content-ref-32223067','lexi-content-ref-27546759','lexi-content-ref-28446744'])">Ref</a></span>) and expert opinion. Higher effluent rates (eg, 4,000 to 5,000 mL/hour) may require higher total daily doses (eg, up to 4 g/day), although the safety of these higher doses has not been evaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32223067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32223067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>IR and IV formulations: </i>750 mg to 1.25 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations and initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dose based on limited data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33217623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33217623'])">Ref</a></span>) and expert opinion.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>IR and IV formulations:</i> 500 mg to 1 g every 12 hours.</p></div>
<div class="block doha drugH1Div" id="F50988936"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Levetiracetam is not extensively metabolized by the liver. In a single-dose pharmacokinetic study, there were no differences in the parameters of patients with Child-Turcotte-Pugh class A and B cirrhosis, but clearance was reduced and half-life was prolonged in patients with Child-Turcotte-Pugh class C cirrhosis compared to healthy volunteers. These changes were attributed to reduced kidney function seen in the Child-Turcotte-Pugh class C patients and not due to altered hepatic function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15961984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15961984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial or dose titration in patients with preexisting liver cirrhosis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class A to C: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15961984','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15961984','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A to C:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening of hepatic function (eg, requiring hospitalization):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A to C</b>: No dosage adjustment necessary; however, consider discontinuation of levetiracetam therapy in patients with suspected levetiracetam-induced liver injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29744119','lexi-content-ref-34235418','lexi-content-ref-35089342','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29744119','lexi-content-ref-34235418','lexi-content-ref-35089342','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55044162"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Levetiracetam may cause CNS depression (<b>asthenia</b>, <b>ataxia</b> [includes abnormal gait, incoordination], <b>fatigue</b>,<b> dizziness</b>, and somnolence [<b>drowsiness</b>]), which may impair physical or mental abilities. Of note, somnolence was the most common reason for levetiracetam discontinuation in the US pivotal partial seizure trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10908898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10908898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; most likely related to activity at the synaptic vesicle protein 2a.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; generally, appear within the first month of treatment and during the up-titration period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18285535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18285535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Somnolence:</p>
<p style="text-indent:-2em;margin-left:8em;">• Doses ≥4 g/day (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10845730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10845730'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Initiation and up-titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10845730','lexi-content-ref-18285535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10845730','lexi-content-ref-18285535'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IV formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16861095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16861095'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Levetiracetam is associated with a variety of delayed hypersensitivity reactions, ranging from mild <b>maculopapular rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31997613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31997613'])">Ref</a></span>) to severe cutaneous adverse reactions (SCARs) including <b>Stevens-Johnson syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332981'])">Ref</a></span>), <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23324778','lexi-content-ref-26893076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23324778','lexi-content-ref-26893076'])">Ref</a></span>), <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26597350','lexi-content-ref-24397826','lexi-content-ref-22764327','lexi-content-ref-25259954','lexi-content-ref-31332981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26597350','lexi-content-ref-24397826','lexi-content-ref-22764327','lexi-content-ref-25259954','lexi-content-ref-31332981'])">Ref</a></span>), and <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23451808','lexi-content-ref-28189379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23451808','lexi-content-ref-28189379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic. Delayed hypersensitivity reactions, including maculopapular eruptions and SCARs, are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied; maculopapular rash usually develops within 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26987035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26987035'])">Ref</a></span>). SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-25259954','lexi-content-ref-NICE.2014','lexi-content-ref-31332981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-25259954','lexi-content-ref-NICE.2014','lexi-content-ref-31332981'])">Ref</a></span>); re-exposure may lead to more rapid onset (usually within 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cross-reactivity: Not adequately described. In patients with a history of DRESS from an aromatic antiseizure medication (eg, phenytoin, carbamazepine), levetiracetam (a non-aromatic antiseizure medication) has been well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29026345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29026345'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric and behavioral abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psychotic symptoms</b>, <b>paranoid ideation</b>, <b>hallucinations</b>, and <b>behavioral changes</b> (including <b>aggressive behavior</b>, <b>agitation</b>, <b>outbursts of anger</b>, <b>anxiety</b>, <b>apathy</b>, <b>confusion</b>, <b>depersonalization</b>, <b>depression</b>, <b>emotional lability</b>, <b>hostility</b>, <b>dyskinesia</b>, <b>irritability</b>, <b>nervousness</b>, <b>neurosis</b>, and <b>personality disorder</b>) may occur in adult and pediatric patients; dose reduction or discontinuation may be required. <b>Suicidal ideation</b> and <b>suicidal tendencies</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12697136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12697136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exact mechanism unknown; some evidence suggests that a negative modulating effect on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors contributes to increased aggressive behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30581496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30581496'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur as early as 1 week after initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Developmental delays or intellectual disability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658982','lexi-content-ref-27255267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658982','lexi-content-ref-27255267'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29753294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29753294'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of epilepsy, (especially frontal lobe epilepsy [including brain tumor-related], absence epilepsy, and difficult-to-treat [“treatment-resistant”] epilepsy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658982','lexi-content-ref-27255267','lexi-content-ref-28238621','lexi-content-ref-14741183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658982','lexi-content-ref-27255267','lexi-content-ref-28238621','lexi-content-ref-14741183'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of psychiatric disorders (eg, ADHD, depression, anxiety, personality disorder, suicidality, or psychotropic or recreational drug use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658982','lexi-content-ref-27255267','lexi-content-ref-14741183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658982','lexi-content-ref-27255267','lexi-content-ref-14741183'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of social deprivation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29753294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29753294'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28238621','lexi-content-ref-29114859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28238621','lexi-content-ref-29114859'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F187610"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences are for all indications and populations (infants, children, adolescents, and adults) unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (diastolic; infants and children &lt;4 years: 17%)<span class="lexi-table-link-container"> (<a aria-label="Increased Blood Pressure table link" class="lexi-table-link" data-table-id="lexi-content-increased-blood-pressure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-blood-pressure')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Blood Pressure</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Blood Pressure" frame="border" id="lexi-content-increased-blood-pressure" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Increased Blood Pressure</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infants and children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (children and adolescents: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (adults: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (adults: 15%)<span class="lexi-table-link-container"> (<a aria-label="Asthenia table link" class="lexi-table-link" data-table-id="lexi-content-asthenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-asthenia')">table 2</a>)</span><span class="table-link" style="display:none;">Asthenia</span>, behavioral changes (including outbursts of anger, apathy, depersonalization, neurosis, personality disorder; children and adolescents: 7% to 38%; adults: 7% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Behavioral Changes table link" class="lexi-table-link" data-table-id="lexi-content-behavioral-changes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-behavioral-changes')">table 3</a>)</span><span class="table-link" style="display:none;">Behavioral Changes</span>, drowsiness (infants, children, adolescents, and adults: 8% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 4</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, fatigue (children and adolescents: 10% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 5</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, headache (14% to 19%), irritability (infants, children, and adolescents: 6% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Irritability table link" class="lexi-table-link" data-table-id="lexi-content-irritability" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-irritability')">table 6</a>)</span><span class="table-link" style="display:none;">Irritability</span>, psychotic symptoms (infants, children, and adolescents: 2% to 17%; adults: 1%)<span class="lexi-table-link-container"> (<a aria-label="Psychotic Symptoms table link" class="lexi-table-link" data-table-id="lexi-content-psychotic-symptoms" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-psychotic-symptoms')">table 7</a>)</span><span class="table-link" style="display:none;">Psychotic Symptoms</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Asthenia" frame="border" id="lexi-content-asthenia" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: Asthenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">439</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Behavioral Changes" frame="border" id="lexi-content-behavioral-changes" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Behavioral Changes</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infants and children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">56</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Myoclonic seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">PGTC seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Irritability" frame="border" id="lexi-content-irritability" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Irritability</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infants and children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">56</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">PGTC seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Psychotic Symptoms" frame="border" id="lexi-content-psychotic-symptoms" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Psychotic Symptoms</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infants and children</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (7% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (3% to 4%), constipation (children and adolescents: 3%), decreased appetite (children and adolescents: 8%), diarrhea (children and adolescents: 6% to 8%), gastroenteritis (children and adolescents: 2%), nausea (5%), upper abdominal pain (children and adolescents: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (children and adolescents: 3%), eosinophilia (children and adolescents: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (children and adolescents: 10%; adults: 1%)<span class="lexi-table-link-container"> (<a aria-label="Aggressive Behavior table link" class="lexi-table-link" data-table-id="lexi-content-aggressive-behavior" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-aggressive-behavior')">table 8</a>)</span><span class="table-link" style="display:none;">Aggressive Behavior</span>, agitation (children and adolescents: 4%)<span class="lexi-table-link-container"> (<a aria-label="Agitation table link" class="lexi-table-link" data-table-id="lexi-content-agitation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-agitation')">table 9</a>)</span><span class="table-link" style="display:none;">Agitation</span>, amnesia (adults: 2%), anxiety (2%)<span class="lexi-table-link-container"> (<a aria-label="Anxiety table link" class="lexi-table-link" data-table-id="lexi-content-anxiety" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anxiety')">table 10</a>)</span><span class="table-link" style="display:none;">Anxiety</span>, ataxia (adult partial-onset seizures: 3%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 11</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, confusion (children and adolescents: 2% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 12</a>)</span><span class="table-link" style="display:none;">Confusion</span>, depression (3% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Depression table link" class="lexi-table-link" data-table-id="lexi-content-depression" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-depression')">table 13</a>)</span><span class="table-link" style="display:none;">Depression</span>, dizziness (5% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 14</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, emotional lability (2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Emotional Lability table link" class="lexi-table-link" data-table-id="lexi-content-emotional-lability" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-emotional-lability')">table 15</a>)</span><span class="table-link" style="display:none;">Emotional Lability</span>, falling (children and adolescents: 3%),<b></b>hostility (adults: 2%)<span class="lexi-table-link-container"> (<a aria-label="Hostility table link" class="lexi-table-link" data-table-id="lexi-content-hostility" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hostility')">table 16</a>)</span><span class="table-link" style="display:none;">Hostility</span>, insomnia (children and adolescents: 5%), lethargy (children and adolescents: 6%), mood changes (children and adolescents: 3%), nervousness (adults: 4%)<span class="lexi-table-link-container"> (<a aria-label="Nervousness table link" class="lexi-table-link" data-table-id="lexi-content-nervousness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nervousness')">table 17</a>)</span><span class="table-link" style="display:none;">Nervousness</span>, pain (adults: 7%), paranoid ideation (children and adolescents: 2%; adults: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Paranoid Ideation table link" class="lexi-table-link" data-table-id="lexi-content-paranoid-ideation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-paranoid-ideation')">table 18</a>)</span><span class="table-link" style="display:none;">Paranoid Ideation</span>, paresthesia (adults: 2%), sedated state (children and adolescents: 2%), vertigo (3% to 5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Aggressive Behavior" frame="border" id="lexi-content-aggressive-behavior" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Aggressive Behavior</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Agitation" frame="border" id="lexi-content-agitation" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Agitation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anxiety" frame="border" id="lexi-content-anxiety" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: Anxiety</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Ataxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Depression" frame="border" id="lexi-content-depression" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Depression</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Myoclonic Seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-Onset Seizure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Emotional Lability" frame="border" id="lexi-content-emotional-lability" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Emotional Lability</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">PGTC seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hostility" frame="border" id="lexi-content-hostility" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Hostility</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nervousness" frame="border" id="lexi-content-nervousness" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Nervousness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Partial-onset seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">769</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">439</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Paranoid Ideation" frame="border" id="lexi-content-paranoid-ideation" rules="all">
<caption style="text-align:center;">
<b>Levetiracetam: Adverse Reaction: </b>
<b>Paranoid Ideation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Levetiracetam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (children and adolescents: 2%), joint sprain (children and adolescents: 2%), neck pain (children and adolescents: 2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (children and adolescents: 2%), diplopia (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (children and adolescents: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2% to 9%), nasal congestion (children and adolescents: 9%), pharyngitis (6% to 7%), pharyngolaryngeal pain (children and adolescents: 7%), rhinitis (2% to 4%), sinusitis (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, leukopenia, lymphocytosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (Mann 2023), torsades de pointes (Mann 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Lee 2014), alopecia (Pitton Rissardo 2023), bullous pemphigoid (Santaliz-Ruiz 2022), eczema, erythema multiforme, maculopapular rash (Kim 2020), psoriasiform eruption (Gencler 2015), skin hyperpigmentation (Algahtani 2017), Stevens-Johnson syndrome (Park 2019), toxic epidermal necrolysis (Duong 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (Coughlin 2022), hyponatremia (Nasrallah 2005), weight loss (Gelisse 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hyperplasia (James 2022), pancreatitis (including acute pancreatitis [Almeida 2013])</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Sexual disorder (Calabrò 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hypogammaglobulinemia (Ozdemir 2018), neutropenia (Taberner Bonastre 2015), pancytopenia (with bone marrow suppression in some cases) (Gohil 2018, Garcia Carretero 2016), thrombocytopenia (Kim 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Jayashankar 2019), hepatitis (including autoimmune hepatitis [Hegazy 2023]), hepatotoxicity (Rogalewski 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Koklu 2014), angioedema (Alkhotani 2012), drug reaction with eosinophilia and systemic symptoms (Bayram 2016), hypersensitivity angiitis (Gupta 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Vickery 2022), choreoathetosis, disturbance in attention, encephalopathy (Verma 2013), exacerbation of epilepsy (SCN8A-related epilepsy), hallucination (including auditory hallucination and visual hallucination) (Tahir 2022), hypomania (Altınöz 2019), manic reaction (Stoppa 2022), memory impairment, myasthenia, myoclonus (Nonaka 2022), obsessive compulsive disorder, panic attack, parkinsonism (Gatto 2006), polyneuropathy (Kapoor 2005), suicidal ideation (Cramer 2003), suicidal tendencies (Cramer 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (Yim 2019), myalgia (Akiyama 2014), rhabdomyolysis (Boucher 2022; Saito 2023), systemic lupus erythematosus (Jadhav 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Hurwitz 2009), granulomatous interstitial nephritis (Chau 2012), interstitial nephritis (Hurwitz 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Fagan 2017), interstitial lung disease (Newsome 2007)</p></div>
<div class="block coi drugH1Div" id="F187623"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis, angioedema) to levetiracetam or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F187607"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution with renal impairment; dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency and status epilepticus; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block dosfc drugH1Div" id="F46216158"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>  Tablets for oral suspension and soluble disintegrating tablet both refer to Spritam.</p></div>
<div class="block foc drugH1Div" id="F187617"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 500 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/100 mL (100 mL); 1000 mg/100 mL (100 mL); 1500 mg/100 mL (100 mL); 500 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/100 mL (100 mL); 1000 mg/100 mL (100 mL); 1500 mg/100 mL (100 mL); 500 mg/5 mL (5 mL); 250 mg/50 mL in NaCl 410 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 100 mg/mL (473 mL) [gluten free, lactose free; contains methylparaben, propylparaben; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (5 mL, 10 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 250 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 500 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 750 mg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 1000 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roweepra: 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roweepra: 500 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roweepra: 750 mg [DSC] [contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roweepra: 1000 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 750 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Spritam: 250 mg, 500 mg, 750 mg, 1000 mg [spearmint flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elepsia XR: 1000 mg, 1500 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra XR: 500 mg, 750 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Roweepra XR: 500 mg [DSC], 750 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 750 mg</p></div>
<div class="block geq drugH1Div" id="F187603"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F187625"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Keppra Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $15.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Keppra Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $2.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levETIRAcetam in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/50 mL (per mL): $0.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/100 mL (per mL): $0.07 - $0.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/100 mL (per mL): $0.13 - $0.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 mg/100 mL (per mL): $0.18 - $0.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levETIRAcetam Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $0.29 - $3.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levETIRAcetam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $0.10 - $1.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Disintegrating Soluble</b> (Spritam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $12.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $12.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $12.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $12.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Elepsia XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $33.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 mg (per each): $41.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Keppra XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $10.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $16.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (levETIRAcetam ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $4.45 - $4.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $6.67 - $6.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Keppra Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $9.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $11.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $16.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $23.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (levETIRAcetam Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.05 - $3.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.08 - $3.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $0.12 - $4.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $0.17 - $11.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Roweepra Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $3.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867350"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (300 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Keppra: 250 mg, 500 mg, 750 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 750 mg, 1000 mg</p></div>
<div class="block admp drugH1Div" id="F52613140"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral solution:</i> Administer with calibrated measuring device (not household teaspoon or tablespoon).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tablets:</i> Manufacturer labeling recommends that tablets should be swallowed whole, not chewed or crushed; however, some studies support crushing and mixing with applesauce, or sprinkling on food; it should be noted that levetiracetam has a bitter taste which may need masked; it has also been administered via enteral feeding tube (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15978308','lexi-content-ref-White.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15978308','lexi-content-ref-White.1'])">Ref</a></span>). In adults, levetiracetam 500 mg tablets were studied crushed and mixed in 120 mL of enteral nutrition formula, 4 oz of applesauce (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15978308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15978308'])">Ref</a></span>), or 10 mL of water and shaken for 5 minutes to disperse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-White.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-White.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Tablets, disintegrating for oral suspension</i> (Spritam): Remove from blister by peeling back the foil (do not push tablet through the foil). Place whole tablet on the tongue with dry hand; follow with a sip of liquid and swallow only after tablet disintegrates; do not swallow intact tablet. Partial/split tablets should not be administered. Tablet disintegrates in a mean time of 11 seconds (ranging from 2 to 27 seconds) in the mouth when taken with a sip of liquid.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternatively, allow whole tablet to disperse in a small volume of liquid (eg, 15 mL or enough to cover the tablet[s]) in a cup; consume entire contents immediately; resuspend any residue in cup by adding an additional small volume of liquid and swallow the full amount.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablets: Swallow tablets whole; do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Vials must be diluted prior to use. Do not use if solution contains particulate matter or is discolored. Discard unused portions; does not contain preservative.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concentrations ≤15 mg/mL:</i> Infuse over 10 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32950862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32950862'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concentrations of 20 mg/mL: </i>Infuse at a rate of 1 mg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31477643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31477643'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concentrations ≤15 mg/mL:</i> Infuse over 15 minutes per the manufacturer; in status epilepticus a rate of 2 to 5 mg/kg/minute has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concentration 50 mg/mL:</i> A 1:1 dilution (50 mg/mL) infused over 5 to 10 minutes (with doses up to 60 mg/kg or 4,500 mg) through a peripheral line has been reported in patients ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774955','lexi-content-ref-28629473','lexi-content-ref-19264738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774955','lexi-content-ref-28629473','lexi-content-ref-19264738'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F187620"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use only; manufacturer recommends infusing over 15 minutes. However, undiluted doses ≤2 g have been administered over 2 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34081297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34081297'])">Ref</a></span>) and undiluted doses ≤4.5 g have been administered over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34164804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34164804'])">Ref</a></span>). Alternatively, a 1:1 dilution with compatible diluent (eg, 1 g levetiracetam per 10 mL diluted in 10 mL of NS; total volume administered: 20 mL) has been administered over 5 minutes with doses up to 4 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34716562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34716562'])">Ref</a></span>) and doses up to 4.5 g over 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774955'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Administer with a calibrated measuring device (not a household teaspoon or tablespoon).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Disintegrating soluble tablet for oral suspension: Remove from blister by peeling back the foil (do not push tablet through the foil). Place whole tablet on the tongue with dry hand, follow with a sip of liquid and swallow only after tablet disintegrates. Do not swallow tablets intact. Partial tablets should not be administered. Tablet disintegrates in a mean time of 11 seconds (ranging from 2 to 27 seconds) in the mouth when taken with a sip of liquid.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternatively, allow whole tablet to disperse in a small volume of liquid (one tablespoon or enough to cover the tablet) in a cup; consume entire contents immediately; resuspend any residue by adding an additional small volume of liquid and swallow the full amount.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Manufacturer labeling recommends that tablets should be swallowed whole, not chewed or crushed; however, some studies support crushing and mixing with applesauce (<b>Note:</b> Levetiracetam has a bitter taste) or administering via enteral feeding tube. Mix with 120 mL of enteral nutrition formula or disperse crushed tablets (500 mg tablet strength studied) in 10 mL of water, shake for 5 minutes to dissolve, and administer immediately via enteral feeding tube (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15978308','lexi-content-ref-White.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15978308','lexi-content-ref-White.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Only administer as whole tablet; do not crush, break, or chew.</p>
<p style="text-indent:-2em;margin-left:8em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR tablet, orally disintegrating tablet, or oral solution.</p></div>
<div class="block sts drugH1Div" id="F187636"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oral solution, tablets, tablets for oral suspension: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Premixed solution for infusion: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Vials for injection: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Admixed solution in NS, LR, or D5W is stable for 4 hours in PVC bags kept at room temperature (<b>Note:</b> The manufacturer's labeling for Keppra injection previously stated the admixed solution is stable for 24 hours in PVC bags at room temperature; this was changed to 4 hours as of April 2016 although there was no change in the formulation (Personal Communication, UCB, Inc. 2016). The manufacturer’s labeling for generic levetiracetam injectable products may have differing recommendations; refer to individual manufacturer’s labeling for details. </p></div>
<div class="block meg drugH1Div" id="F7874650"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Elepsia XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F204417s004lbl.pdf%23page%3D25&amp;token=e%2BmzcwwXxX7F0FzbZf%2FCbpoJ50x4CH12EjNbEhDS9ubxDUssgOLLSgS4pIKRKSS5qmJVTEI97eCg8yd8ue2fRHbuL3Rnd%2FAkH6wSY0X3IUYypSAJUyJd86qD14ZSPiLG&amp;TOPIC_ID=12910" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204417s004lbl.pdf#page=25</a></p>
<p style="text-indent:-2em;margin-left:4em;">Keppra: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021035s113%2C021505s052lbl.pdf%23page%3D32&amp;token=e2SDMMX8dtUl5Pf7QHfAaEUqudlr%2Bpzj74McgC15lFFk8lqmW2CYKoxEC6HRFwwGBuKSFM0IpytOWv2lDPb4BHejbPCNVnvHQlDbmRuMQHJ4PCY5cMj%2Bg8nJ91VFKqZ9&amp;TOPIC_ID=12910" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021035s113,021505s052lbl.pdf#page=32</a></p>
<p style="text-indent:-2em;margin-left:4em;">Keppra XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022285s034lbl.pdf%23page%3D26&amp;token=5UHPY8HnVgW8qE9tMPBAe5yI6Km%2BYLYkP2oyjK8315kHb46eSqbOQdYEbTtyfjyCiffVkfvLBysbNj4hCk4Q1uvmEqCyQXmO3vg2jltv2Lhx3lWvPwpC3Rm8rVrPpbrG&amp;TOPIC_ID=12910" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022285s034lbl.pdf#page=26</a></p>
<p style="text-indent:-2em;margin-left:4em;">Spritam: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F207958s023lbl.pdf%23page%3D36&amp;token=eUDM%2BMClApUWiANYFPwpjcOMrDZFNBtiuKDhNs1MBFraUA8YlfZOraeU1iNnOVtApWjsv9M2ueJBDwL8%2FZh75tojQqcqXW8FxpLplBQaJBCiiej4kZg6gRZj2PUXTQ6r&amp;TOPIC_ID=12910" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207958s023lbl.pdf#page=36</a></p></div>
<div class="block usep drugH1Div" id="F53567496"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution and immediate-release tablets: Treatment of partial onset seizures, monotherapy or adjunctive (FDA approved in ages ≥1 month and adults); adjunctive therapy in the treatment of myoclonic seizures (including juvenile myoclonic epilepsy) (FDA approved in ages ≥12 years and adults); adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy (FDA approved in ages ≥6 years and adults); has also been used for treatment of neonatal seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets for oral suspension: Spritam: Treatment of partial onset seizures, monotherapy or adjunctive (FDA approved in ages ≥4 years weighing &gt;20 kg and adults); adjunctive therapy in the treatment of juvenile myoclonic epilepsy (FDA approved in ages ≥12 years); and adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy (FDA approved in ages ≥6 years and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablets (eg, Elepsia XR, Keppra XR): Treatment of partial onset seizures (monotherapy: Keppra XR; adjunctive: Elepsia, Keppra XR) (FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: When oral administration is temporarily not feasible monotherapy or adjunctive therapy in the treatment of partial onset (focal) seizures (FDA approved in ages ≥1 month and adults), adjunctive therapy for myoclonic seizures (including juvenile myoclonic epilepsy) (FDA approved in ages ≥12 years and adults), and adjunctive therapy for primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy (FDA approved in ages ≥6 years and adults); has also been used for treatment of status epilepticus as second-line therapy (after failure of benzodiazepine treatment) or acute repetitive seizure activity.</p></div>
<div class="block mst drugH1Div" id="F187675"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Keppra may be confused with Keflex, Keppra XR</p>
<p style="text-indent:-2em;margin-left:4em;">LevETIRAcetam may be confused with brivaracetam, lamoTRIgine, levOCARNitine, levoFLOXacin</p>
<p style="text-indent:-2em;margin-left:4em;">Potential for dispensing errors between Keppra and Kaletra (lopinavir/ritonavir)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299586"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F187612"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: LevETIRAcetam may diminish the therapeutic effect of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: LevETIRAcetam may diminish the therapeutic effect of Brivaracetam. Specifically, the therapeutic effect of brivaracetam may be diminished and/or negligible when given to patients already receiving levetiracetam.  Management: Consider alternatives to the combined use of levetiracetam and brivaracetam due to an apparent lack of brivaracetam effectiveness in patients receiving levetiracetam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: LevETIRAcetam may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: LevETIRAcetam may enhance the anticoagulant effect of Dabigatran Etexilate. LevETIRAcetam may diminish the therapeutic effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: LevETIRAcetam may diminish the therapeutic effect of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin: LevETIRAcetam may enhance the CNS depressant effect of Gabapentin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: LevETIRAcetam may enhance the CNS depressant effect of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: LevETIRAcetam may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: LevETIRAcetam may enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: LevETIRAcetam may enhance the CNS depressant effect of Primidone. Primidone may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: LevETIRAcetam may decrease the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: LevETIRAcetam may enhance the CNS depressant effect of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F187637"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may delay, but does not affect the extent of absorption. Management: Administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F187626"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Levetiracetam crosses the placenta and can be detected in the newborn following delivery (Johannessen 2005; López-Fraile 2009; Tomson 2007).</p>
<p style="text-indent:0em;margin-top:2em;">An increase in the overall rate of major congenital malformations has not been observed following maternal use of levetiracetam. Available studies have not been large enough to determine if there is an increased risk of specific birth defects (Hernández-Díaz 2012; Mawhinney 2013; Mølgaard-Nielsen 2011; Vajda 2012). In general, maternal polytherapy with antiseizure drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of women taking antiseizure medications may be at an increased risk of SGA and a 1 minute APGAR score &lt;7 (Harden 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, plasma concentrations of levetiracetam gradually decrease during pregnancy, especially during the third trimester; patients should be closely monitored during pregnancy and postpartum.</p>
<p style="text-indent:0em;margin-top:2em;">A registry is available for women exposed to levetiracetam during pregnancy: Pregnant women may enroll themselves into the North American Antiepileptic Drug (AED) Pregnancy Registry (888-233-2334 or http://www.aedpregnancyregistry.org/).</p></div>
<div class="block mopp drugH1Div" id="F53567497"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;text-align:justify;display:inline">Seizure frequency, duration, and severity; CNS depression; psychiatric and behavioral symptoms; diastolic blood pressure in pediatric patients &lt;4 years of age; renal function; CBC; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes) </p></div>
<div class="block rerp drugH1Div" id="F54399819"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic reference range: <b>Note: </b>There is no clear correlation with therapeutic levels and efficacy or tolerability; base dosing on therapeutic response as opposed to serum concentrations. However, therapeutic drug levels may be useful in neonates, pregnant women, elderly patients, and patients on enzyme-inducing drugs or with renal insufficiency due to the wide range of alterations in clearance (Sourbron 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum samples: Draw trough just before next dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Epilepsy: 12 to 46 mcg/mL (SI: 70 to 270 micromole/L) (AGNP [Hiemke 2018]; Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Laboratory alert level: 50 mcg/mL (SI: 294 micromole/L) (AGNP [Hiemke 2018]).</p></div>
<div class="block pha drugH1Div" id="F187606"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The precise mechanism by which levetiracetam exerts its antiseizure effect is unknown. However, several studies have suggested the mechanism may involve one or more of the following central pharmacologic effects: inhibition of voltage-dependent N-type calcium channels; facilitation of GABA-ergic inhibitory transmission through displacement of negative modulators; reduction of delayed rectifier potassium current; and/or binding to synaptic proteins which modulate neurotransmitter release.</p></div>
<div class="block phk drugH1Div" id="F187622"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and almost complete.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Food decreases C<sub>max</sub> by 20% and delays time to C<sub>max</sub> (T<sub>max</sub>) by 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Intake of a high-fat, high-calorie breakfast before the administration results in a higher C<sub>max</sub> and longer median T<sub>max</sub>; the median T<sub>max</sub> is 2 hours longer in the fed state.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Similar to total body water.</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates: 1.01 ± 0.13 L/kg (range: 0.81 to 1.24 L/kg) (Sharpe 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;4 years of age: 0.63 ± 0.08 L/kg (Glauser 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years of age: 0.72 ± 0.12 L/kg (Pellock 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.5 to 0.7 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not extensive; 24% of dose is metabolized by enzymatic hydrolysis of acetamide group (major metabolic pathway; hydrolysis occurs primarily in the blood; not cytochrome P450 dependent); two minor metabolites (one via hydroxylation of 2-oxo-pyrrolidine ring and one via opening of the 2-oxo-pyrrolidine ring in position 5) are also formed; metabolites are inactive and renally excreted.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 100%; bioavailability of ER tablets is similar to IR tablets; tablets, oral solution, and injection are bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Increased in patients with renal impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates (PNA ≤5 days at therapy initiation) (Sharpe 2012):</p>
<p style="text-indent:-2em;margin-left:6em;">Day 1 of therapy : 18.5 ± 7.1 hours (range: 8.8 to 32.7 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Day 7 of therapy: 9.1 ± 2 hours (range: 5.3 to 12.7 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;4 years of age: 5.3 ± 1.3 hours (Glauser 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to 12 years of age: 6 ± 1.1 hours (Pellock 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~6 to 8 hours; ER tablet: ~7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 5 to 30 minutes (Ramael 2006a).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Fasting infants and children &lt;4 years of age: 1.4 ± 0.9 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate release: Fasting adults and children: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Extended release: ~4 hours; median time to peak is 2 hours longer in the fed state.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (66% as unchanged drug and 27% as inactive metabolites); undergoes glomerular filtration and subsequent partial tubular reabsorption.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Correlated with CrCl; clearance is decreased in patients with renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates (PNA ≤5 days at therapy initiation) (Sharpe 2012):</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1 of therapy : 0.71 ± 0.27 mL/minute/kg (range: 0.38 to 1.42 mL/minute/kg).</p>
<p style="text-indent:-2em;margin-left:8em;">Day 7 of therapy: 1.31 ± 0.35 mL/minute/kg (range: 0.88 to 2.37 mL/minute/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;6 months: 1.23 mL/minute/kg (Glauser 2007).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children 6 months to 4 years of age: 1.57 mL/minute/kg (Glauser 2007).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 12 years of age: 1.43 mL/minute/kg; 30% to 40% higher than adults on a per kg basis (Pellock 2001).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.96 mL/minute/kg.</p></div>
<div class="block phksp drugH1Div" id="F51198316"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased and half-life is increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is decreased in patients with severe (Child-Pugh class C) impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Half-life is increased and clearance is decreased.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: C<sub>max</sub> and AUC are higher in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187628"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adcitan | Anolet | Convolt | Epicitam | Kepetam | Keppra | Lepsenal | Letram | Levekepp | Levetiracetam sandoz | Tiraptic</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Callexe | Callexe xr | Equilea | Keppra | Lafonten | Leptam | Levaxon | Levecom | Levenova | Levetiracetam richet | Levital | Levron | Molival | Racetam | Vecetam</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eprilexan | Keppra | Levebon | Levelept | Levetiracetam 1a pharma | Levetiracetam accord | Levetiracetam actavis | Levetiracetam aristo | Levetiracetam Bluefish | Levetiracetam easypharm | Levetiracetam G.L | Levetiracetam genericon | Levetiracetam hikma | Levetiracetam krka | Levetiracetam medicamentum | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam stada | Levetiracetam sun | Levetiracetam ucb | Prepalepan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo levetiracetam | Chemmart Levetiracetam | Hospira Levetiracetam | Kepcet | Keppra | Kerron | Kevtam | Levactam | Levetiracetam aft | Levetiracetam an | Levetiracetam Generic Health | Levetiracetam juno | Levetiracetam mylan | Levetiracetam pfizer | Levetiracetam sandoz | Levetiracetam sun | Levi | Levitaccord | Levitam | Noumed levetiracetam | Terry White Chemists Levetiracetam</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Citazar | Eletam | Epicet | Iracet | Levefix | Levetira | Leviceta | Levipil | Neurocet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam actavis | Levetiracetam apotex | Levetiracetam aspen | Levetiracetam eg | Levetiracetam kela | Levetiracetam sandoz | Levetiracetam teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alvotiracetam | Epiletam | Keppra | Lepsitam | Levebon | Levetiracetam accord | Levetiracon | Noepix | Normeg | Repitend</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Antara | Etira | Iludral | Keppra | Keppra xr | Spark | Tam</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Lev desitin | Levetiracetam actavis | Levetiracetam desitin | Levetiracetam helvepharm | Levetiracetam mepha | Levetiracetam sandoz | Levetiracetam Spirig | Levetiracetam spirig hc | Levetiracetam teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ceumid | Convultam | Keppra | Kopodex | Kopodex xr | Kredit | Leoval | Levepsy | Levevitae | Prebb</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Keppra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acizan | Ceumid | Convulam | Etitam | Ictafin | Kepertan | Keppra | Kopodex | Kopodex xr | Levevitae | Levipil | Levore | Levtec | Monavri xr | Pegra | Ubinona | Vecetam | Xitucira</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dretacen | Epiletam | Kapidokor | Keppra | Letiramyl | Levelanz | Levetiracetam accord | Levetiracetam actavis | Levetiracetam apotex | Levetiracetam aurovitas | Levetiracetam desitin | Levetiracetam G.L. pharma | Levetiracetam mylan | Levetiracetam orion | Levetiracetam pmcs | Levetiracetam stada | Levetiracetam teva | Levetiracetam ucb | Matever | Normeg | Prepalepan | Pterocyn | Repitend | Trund</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kepcet | Keppra | Kevesy | Levepil | Levetiracetam 1a pharma | Levetiracetam aaa | Levetiracetam accord | Levetiracetam Acis | Levetiracetam actavis | Levetiracetam al | Levetiracetam Aliud pharma | Levetiracetam Altan | Levetiracetam amarox | Levetiracetam ametas | Levetiracetam amneal | Levetiracetam aristo | Levetiracetam aurobindo | Levetiracetam axcount | Levetiracetam basics | Levetiracetam Betapharm | Levetiracetam biomo | Levetiracetam Bluefish | Levetiracetam bristol Lab | Levetiracetam ct | Levetiracetam desitin | Levetiracetam ever | Levetiracetam Fair Med Healthcare | Levetiracetam glenmark | Levetiracetam Heumann | Levetiracetam Hexal | Levetiracetam hikma | Levetiracetam holsten | Levetiracetam Hormosan | Levetiracetam hospira | Levetiracetam Juta | Levetiracetam micro labs | Levetiracetam mylan | Levetiracetam neuraxpharm | Levetiracetam normon | Levetiracetam pfizer | Levetiracetam puren | Levetiracetam ratiopharm | Levetiracetam stada | Levetiracetam sun | Levetiracetam TAD | Levetiracetam tillomed | Levetiracetam ucb | Levetiracetam Winthrop | Levetiracetam zentiva | Levetiragamma | Matever</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Callexe | Callexe xr | Ceumid | Convultin | Derinoe | Eurolevetir | Evetiram | Felcetam | Ipnopan | Keppra | Kopodex | Leoval | Lepcetam | Letracem | Levesam | Lortam | Meldiban | Tamlet t</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Antara | Callexe | Callexe 1000 | Callexe 500 | Callexe xr 500 | Callexe xr 750 | Ceumid | Contepil | Derinoe xr | Etabyx | Keppra | Kopodex | Leoval | Levecom | Levetirox | Levipil | Moditen | Tamlet t | Xitucira</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Epilem | Keppra | Kevesy | Levetam | Levetiracetam accord | Levetiracetam gsk | Levetiracetam pharmaswiss | Matever | Normeg</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Futatreat | Kalopratam | Kepilepsy | Keppra | Kepradil | Levectam | Levepex | Levepsy | Liptitam | Matrilive | Olmedersa | Seizurless | Sycocetam | Tiralepsy | Tiratam | Trinovume</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Laurak | Levetiracetam actavis | Levetiracetam almus | Levetiracetam alter | Levetiracetam amneal | Levetiracetam apotex | Levetiracetam aristo | Levetiracetam aurobindo | Levetiracetam aurovitas | Levetiracetam Bluefish | Levetiracetam brill pharma | Levetiracetam cinfa | Levetiracetam Combino | Levetiracetam combino pharm | Levetiracetam combix | Levetiracetam farmalider | Levetiracetam g.e.s | Levetiracetam hospira | Levetiracetam kern pharma | Levetiracetam krka | Levetiracetam Mabo | Levetiracetam mylan | Levetiracetam Norm | Levetiracetam normon | Levetiracetam pensa | Levetiracetam Qualigen | Levetiracetam ranbaxy | Levetiracetam ratiopharm | Levetiracetam Sandos | Levetiracetam sandoz | Levetiracetam sanovel | Levetiracetam stada | Levetiracetam sun | Levetiracetam tarbis | Levetiracetam Tecnimede | Levetiracetam teva | Levetiracetam ucb | Levetiracetam zentiva | Tirbas</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Kevesy | Levetiracetam 1a farma | Levetiracetam accord | Levetiracetam actavis | Levetiracetam aspen | Levetiracetam Avansor | Levetiracetam hospira | Levetiracetam orion | Levetiracetam sandoz | Levetiracetam stada | Levetiracetam sun | Matever</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Leptax | Levetiracetam accord | Levetiracetam actavis | Levetiracetam aguettant | Levetiracetam alter | Levetiracetam arrow | Levetiracetam biogaran | Levetiracetam cristers | Levetiracetam eg | Levetiracetam Evolugen | Levetiracetam hikma | Levetiracetam hospira | Levetiracetam krka | Levetiracetam mylan | Levetiracetam ranbaxy | Levetiracetam sandoz | Levetiracetam sun | Levetiracetam teva | Levetiracetam zentiva | Levetiracetam zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Desitrend | Genlev | Keppra | Kevesy | Levetiracetam accord | Levetiracetam amarox | Levetiracetam bristol Lab | Levetiracetam brown | Levetiracetam hikma | Levetiracetam hospira | Levetiracetam teva | Levetiracetam wockhardt</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Kepricet | Letira | Levetiracetam pharmaswiss | Levetiracetam teva | Levetiracetam ucb | Levetiracetam/actavis | Levetiracetam/galenica | Levetiracetam/hospira | Levetiracetam/mylan | Levetiracetam/sandoz | Lyberen | Matever | Newlev | Vetiracem</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo levetiracetam | Keppra | Levetiracetam teva</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam Belupo | Lyvam | Nirval</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kapidokor | Keppra | Levedia | Levelan | Levetiracetam accord | Levetiracetam actavis | Levetiracetam pharmaswiss | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam stada | Levetiracetam teva | Levetiracetam ucb | Levetiragamma | Levil | Matever</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Antilep actavis | Kepra | Lethira | Levexa | Levitam</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam ratiopharm | Levetiracetam thame | Mevluxa</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Keppra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amendo | Confilev | Emlevo | Epibrus | Epictal | Epifast | Epikey | Epiletra | Epilive | Epinext | Episeize | Epitra | Epitra er | Epiwel | Eplepmax | Fritolev | Fritolev xr | Ictacetam | Keppra | L tam | Lecetam | Lenerve | Lev | Levacetam | Levapie | Levecad | Levecon | Levecon sr | Levefree | Levemex | Levemex od | Levenue | Levepsy | Levera | Levesam | Levesol | Levetee | Leveteo | Levetor | Levetrix | Levexx | Levialfa | Levicent | Levictus | Levigress | Levihop | Levilex | Levinxt | Levipil | Levisign | Levitam | Levitra 250 | Levitram | Levitune | Levitune 500 xr | Levoraka | Levroxa | Levtam | Livatira | Livrich | Lysiprin | Neolet | Qlexin | Tiramax | Torleva | Trinix xr | Uleev | Verocet | Vetira</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Kepracetam | Levemax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Epitiram | Exitelev | Grifoxina | Italept | Keppra | Levetiracetam accord | Levetiracetam actavis | Levetiracetam almus | Levetiracetam aristo | Levetiracetam aurobindo | Levetiracetam Aurobindo Italia | Levetiracetam Bluefish | Levetiracetam doc | Levetiracetam DOCgen | Levetiracetam eg | Levetiracetam hikma | Levetiracetam hospira | Levetiracetam krka | Levetiracetam mylan | Levetiracetam pensa | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam sun | Levetiracetam tecnigen | Levetiracetam teva | Levetiracetam tillomed | Levetiracetam zentiva | Matever | Unipitiram</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Antagra | Epitam | Epixx | Keppra | Kotral | Seizam | Tiraptic</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">E keppra | Levetiracetam jg | Levetiracetam meiji | Levetiracetam nissin | Levetiracetam sandoz | Levetiracetam towa | Levetiracetam vtrs</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Lerace | Levigress | Levipil | Torleva</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dongkoo levetiracetam | Epilatam | Epild | Episk | Kepiram | Keppabear | Keppra | Keppra xr | Kepreptol | Kepreptol er | Keratam | Leppil | Letiram | Levecetam | Levecure | Levetiqual | Levetiram | Levewon | Levira | Levirotin | Levitam | Levpil | Pfizer levetiracetam | Q pam | Q pam xr | Staretam | Tinacetam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Keppra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Epitam | Kepam | Kepcitam | Keppra | Levetiracetam arrow | Levetiracetam biogaran | Levetiracetam TAD | Levipram | Zitera</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dretacen | Keppra | Levetiracetam accord | Matever</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam accord | Levetiracetam desitin | Levetiracetam pharmaswiss | Levetiracetam teva | Levetiracetam ucb | Levetrim | Matever</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Keppra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">6 ur | Alemap | Autevazen | Biocet | Branche | Ellcetar | Ellekta | Endoestat | Evicovac | Exitelev | Genamar | Ivetra | Keppra | Keppra xr | Korcetav | Lecer | Lepicet | Leprezil | Leprezil sl | Levetiracetam accord | Levexx | Leviflex | Levipil | Loraxtan | Lpsyrid | Movuren | Pisarpek | Tamlet s | Tamlet t | Tayix | Tirapil | Tiraprob | Urcadiol | Vetrilep | Vexager | Vulsoran | Zeletvann</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Epitech | Keppra | Letram | Levera | Levet | Torleva</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Keppra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Kevesy | Levetiracetam accord | Levetiracetam actavis | Levetiracetam amarox | Levetiracetam aurobindo | Levetiracetam cf | Levetiracetam hospira | Levetiracetam pharmacin | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam sun | Levetiracetam teva | Matever</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Kevesy | Levetiracetam accord | Levetiracetam amneal | Levetiracetam aspen | Levetiracetam hospira</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Everet | Keppra | Levetiracetam aft | Noumed levetiracetam</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ceumid | Keppra | Kopodex | Leoval | Letivce | Levevitae | Levexyl | Levipil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Akucetam | Devetam | Dretacen | Epira | Epsytam | Focale | Ivetra | Julitam | Kepdin | Keppra | Lentira | Letram | Levipil | Levit | Levtrawell | Vexlev</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Antilep | Barlev | Cetratame | Devenda | Elicia | Elicia er | Emscot | Epian | Epicetam | Episaf | Eplipsa | Eppra | Evic | Fitzloc | Hevetam | Keppet | Keppra | Keptiron | Klevra | Le tact | Lecetam | Leepra | Lefaz | Lekra | Lepsi | Lerace | Levectam | Levenue | Levepsy | Levetec | Levetfold | Leveticam | Levetram | Levezine | Levic | Levital | Levixa | Levotam | Levra | Lumark | Lumark xr | LVT | Recetam | Seizoram | Speppra | Speppra xr | Tamel | Tamlev | Tiracit | Tiram | Tirasynth | Tiratam | Vetrawin | Vicet | Xeticam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cezarius | Eliptus | Eprilexan | Keppra | Levebon | Levetiracetam accord | Levetiracetam actavis | Levetiracetam apotex | Levetiracetam aurovitas | Levetiracetam Bluefish | Levetiracetam generics | Levetiracetam mylan | Levetiracetam NeuroPharma | Levetiracetam orion | Levetiracetam pharmaswiss | Levetiracetam ranbaxy | Levetiracetam stada | Levetiracetam teva | Levetiracetam Zdrovit | Levetiragamma | Normeg | Polkepral | Prepalepan | Symetra | Trund | Vetira | Zelta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Elepsia xr | Keppra | Keppra xr | Levetiracetam ER | Roweepra | Spritam</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Laurak | Levetiracetam accord | Levetiracetam actavis | Levetiracetam actavis group | Levetiracetam alter | Levetiracetam aristo | Levetiracetam aurobindo | Levetiracetam aurovitas | Levetiracetam Bluefish | Levetiracetam bluepharma | Levetiracetam Ciclum | Levetiracetam ciclum farma | Levetiracetam Cinaz | Levetiracetam cinfa | Levetiracetam Combino | Levetiracetam Farmoz | Levetiracetam generis | Levetiracetam gp | Levetiracetam hikma | Levetiracetam jaba | Levetiracetam Labesfal | Levetiracetam medirex | Levetiracetam mepha | Levetiracetam normon | Levetiracetam pensa | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam tecnigen | Levetiracetam teva | Levetiracetam tirbas | Levetiracetam Tolife | Levetiracetam ucb | Levetiracetam vitoria | Levetiracetam wynn | Levetiracetam zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ceumid | Ceumid xr | Kopodex | Kopodex xr | Levaxon | Levecom | Levetam | Levetiracetam bauel top | Levetiracetam dallas | Levetiracetam heisecke | Levetiracetam imedic | Levetiracetam libra | Levetiracetam prosalud | Levetiracetam seven | Molival | Vecetam</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Antagra XR | Epitam | Epixx | Kepam | Kepcitam | Keppra | Tiraptic</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Epiletam | Keppra | Levelanz | Levetiracetam accord | Levetiracetam sun | Levetiracetam teva | Trund | Vetira</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Elsetor | Epikepran | Epiterra | Epiterra long | Epitropil | Kepayra vero | Keppra | Komviron | Konvilept | Letiram | Levetinol | Levetiracetam alium | Levetiracetam canon | Tirapol | Zenicetam</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Arpek | Efram XR | Epitam | Kepam | Keppra | Lavie | Letirem | Levetam | Vales | Vitram</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Keppra Ebb | Kevesy | Levetira Accord | Levetira actavis group | Levetiracetam 1a farma | Levetiracetam 2care4 | Levetiracetam accord | Levetiracetam actavis | Levetiracetam amneal | Levetiracetam aspen | Levetiracetam Bluefish | Levetiracetam ebb | Levetiracetam hospira | Levetiracetam medartuum | Levetiracetam orion | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam stada | Levetiracetam sun | Levetiracetam teva | Matever</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam aft | Tietari</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Keppra | Levetiracetam accord | Levetiracetam actavis | Levetiracetam pharmaswiss | Levetiracetam sandoz | Levetiracetam sun | Levetiracetam teva | Lyvam | Matever</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Epiletam | Keppra | Levemed | Levetiracetam accord | Levetiracetam actavis | Levetiracetam pharmaswiss | Levetiracetam ratiopharm | Levetiracetam sandoz | Levetiracetam stada | Levetiracetam teva | Levetiracetam ucb | Matever | Pterocyn | Repitend | Trund</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Focale | Keppra | Lecetam | Levacore | Levetiracetam hainan poly | Torleva</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Antiomal | Epitam | Epixx | Keppra | Levet | Vetira</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anlev | Epi No | Epilecure | Epilem | Epileptal | Epitam | Epixx | Keppra | L Cetam | Leptica | Lesitam | Lev-End | Levebrain | Levemax | Levesto | Levetam | Netrolex | Odyparx | Tirgen | Vetria</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Epilen | Keppra | Letampin | Levetir | Levim | Levotam | Nobelin | Pharacetam | Ufree</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Deseiz | Keppra | Levenium | Levetiracetam teva | Levicitam | Logufen | Normeg</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Quetra | Torleva</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ceumid | Keppra | Kodex | Levecom | Levetam | Levetiracetam libra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ancitam | Ceumid | Keppra | Kopodex | Lepcetam | Levedalt | Levetiracetam bluepharma | Levetuni</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Intalevi | Meyerlecetam | Sunlevira | Zokicetam</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Citara | Dyna Levetiracetam | Epikepp | Kelev | Keppra | Levetiracetam biotech | Levetiracetam unicorn | Redilev | Torcetam</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Letram | Torleva</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34081297">
<a name="34081297"></a>Adams T, Greathouse K. Evaluation of time to administration, benzodiazepine use, and safety of intravenous push levetiracetam in a neuro-spine intensive care unit. <i>Neurocrit Care.</i> 2021;35(3):789-793. doi:10.1007/s12028-021-01237-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/34081297/pubmed" id="34081297" target="_blank">34081297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25667895">
<a name="25667895"></a>Akiyama H, Haga Y, Sasaki N, Yanagisawa T, Hasegawa Y. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. <i>Epilepsy Behav Case Rep</i>. 2014;2:152-155. doi:10.1016/j.ebcr.2014.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/25667895/pubmed" id="25667895" target="_blank">25667895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29344468">
<a name="29344468"></a>Algahtani H, Marghalani S, Satti M, Shirah B. Levetiracetam-induced skin hyperpigmentation: an extremely rare undesirable side effect. <i>J Epilepsy Res</i>. 2017;7(2):106-108. doi:10.14581/jer.17016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29344468/pubmed" id="29344468" target="_blank">29344468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34716562">
<a name="34716562"></a>Alkazemi A, McLaughlin KC, Chan MG, Schontz MJ, Anger KE, Szumita PM. Safety of intravenous push levetiracetam compared to intravenous piggyback at a tertiary academic medical center: a retrospective analysis. <i>Drug Saf.</i> 2022;45(1):19-26. doi:10.1007/s40264-021-01122-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/34716562/pubmed" id="34716562" target="_blank">34716562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22524985">
<a name="22524985"></a>Alkhotani A, McLachlan RS. Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. <i>Seizure</i>. 2012;21(5):407-408. doi:10.1016/j.seizure.2012.03.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22524985/pubmed" id="22524985" target="_blank">22524985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23254916">
<a name="23254916"></a>Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM. Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report. <i>Pancreas</i>. 2013;42(1):177-178. doi:10.1097/MPA.0b013e3182588c91<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23254916/pubmed" id="23254916" target="_blank">23254916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31620273">
<a name="31620273"></a>Altınöz AE, Tosun Altınöz Ş, Güzel Biltekin B, Can Kaya M. Levetiracetam induced hypomania: a case report. <i>Ther Adv Drug Saf</i>. 2019;10:2042098619876754. doi:10.1177/2042098619876754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31620273/pubmed" id="31620273" target="_blank">31620273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29658982">
<a name="29658982"></a>Andres E, Kerling F, Hamer H, Winterholler M. Behavioural changes in patients with intellectual disability treated with brivaracetam. <i>Acta Neurol Scand</i>. 2018;138(3):195-202. doi: 10.1111/ane.12943.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29658982/pubmed" id="29658982" target="_blank">29658982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24739070">
<a name="24739070"></a>Bahte SK, Hiss M, Lichtinghagen R, Kielstein JT. A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient. <i>BMC Nephrol</i>. 2014;15:49. doi:10.1186/1471-2369-15-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24739070/pubmed" id="24739070" target="_blank">24739070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25929593">
<a name="25929593"></a>Bansal AD, Hill CE, Berns JS. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. <i>Semin Dial</i>. 2015;28(4):404-412. doi:10.1111/sdi.12385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/25929593/pubmed" id="25929593" target="_blank">25929593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26597350">
<a name="26597350"></a>Bayram AK, Canpolat M, Çınar SL, et al. Drug reaction with eosinophilia and systemic symptoms syndrome induced by levetiracetam in a pediatric patient. <i>J Emerg Med</i>. 2016;50(2):e61-6. doi: 10.1016/j.jemermed.2015.10.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26597350/pubmed" id="26597350" target="_blank">26597350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10845730">
<a name="10845730"></a>Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. <i>Seizure.</i> 2000;9(2):80-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/10845730/pubmed" id="10845730" target="_blank">10845730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26987035">
<a name="26987035"></a>Bhoi SK, Kalita J, Misra UK. Skin rash following levetiracetam. <i>Seizure</i>. 2016;37:45-47. doi: 10.1016/j.seizure.2016.02.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26987035/pubmed" id="26987035" target="_blank">26987035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36381889">
<a name="36381889"></a>Boucher KS, Dedhia N, Bommisetty D. Levetiracetam-induced rhabdomyolysis following medication re-initiation. <i>Cureus</i>. 2022;14(10):e30042. doi:10.7759/cureus.30042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/36381889/pubmed" id="36381889" target="_blank">36381889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736657">
<a name="27736657"></a>Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. <i>Epilepsy Behav</i>. 2016;64(pt A):110-115. doi: 10.1016/j.yebeh.2016.09.030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27736657/pubmed" id="27736657" target="_blank">27736657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15961984">
<a name="15961984"></a>Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. <i>Clin Pharmacol Ther</i>. 2005;77(6):529-541. doi:10.1016/j.clpt.2005.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/15961984/pubmed" id="15961984" target="_blank">15961984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi: 10.1007/s40629-015-0052-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17283312">
<a name="17283312"></a>Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. <i>Neurology</i>. 2007;68(6):402-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17283312/pubmed" id="17283312" target="_blank">17283312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27255267">
<a name="27255267"></a>Brodie MJ, Besag F, Ettinger AB, wt al. Epilepsy, antiepileptic drugs, and aggression: An evidence-based review. <i>Pharmacol Rev</i>. 2016;68(3):563-602. doi: 10.1124/pr.115.012021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27255267/pubmed" id="27255267" target="_blank">27255267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23340273">
<a name="23340273"></a>Calabrò RS, Bramanti P. Levetiracetam-induced sexual disorders. <i>Seizure</i>. 2013;22(4):329. doi:10.1016/j.seizure.2013.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23340273/pubmed" id="23340273" target="_blank">23340273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10908898">
<a name="10908898"></a>Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236-242. doi: 10.1212/wnl.55.2.236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/10908898/pubmed" id="10908898" target="_blank">10908898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26069773">
<a name="26069773"></a>Chau K, Yong J, Ismail K, Griffith N, Liu M, Makris A. Levetiracetam-induced severe acute granulomatous interstitial nephritis. <i>Clin Kidney J</i>. 2012;5(3):234-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26069773/pubmed" id="26069773" target="_blank">26069773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33217623">
<a name="33217623"></a>Chappell K, Kimmons LA, Haller JT, Canada RB, He H, Hudson JQ. Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. <i>J Crit Care.</i> 2021;61:216-220. doi:10.1016/j.jcrc.2020.10.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/33217623/pubmed" id="33217623" target="_blank">33217623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28238621">
<a name="28238621"></a>Chen B, Detyniecki K, Choi H, et al. Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy. <i>Eur J Paediatr Neurol</i>. 2017;21(3):441-449. doi: 10.1016/j.ejpn.2017.02.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28238621/pubmed" id="28238621" target="_blank">28238621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31830677">
<a name="31830677"></a>Chu SS, Wang HJ, Zhu LN, Xu D, Wang XP, Liu L. Therapeutic effect of intravenous levetiracetam in status epilepticus: a meta-analysis and systematic review. <i>Seizure</i>. 2019;74:49-55. doi: 10.1016/j.seizure.2019.11.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31830677/pubmed" id="31830677" target="_blank">31830677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26669640">
<a name="26669640"></a>Chung MG, O'Brien NF. Prevalence of early posttraumatic seizures in children with moderate to severe traumatic brain injury despite levetiracetam prophylaxis. <i>Pediatr Crit Care Med</i>. 2016;17(2):150-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26669640/pubmed" id="26669640" target="_blank">26669640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556195">
<a name="22556195"></a>Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2012;43(6):1711-1737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22556195/pubmed" id="22556195" target="_blank">22556195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21944894">
<a name="21944894"></a>Contin M, Mohamed S, Albani F, Riva R, Baruzzi A. Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy [published correction appears in <i>Epilepsy Res</i>. 2012;101(3):295]. <i>Epilepsy Res</i>. 2012;98(2-3):130-134. doi: 10.1016/j.eplepsyres.2011.08.020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21944894/pubmed" id="21944894" target="_blank">21944894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35530900">
<a name="35530900"></a>Coughlin P, Patel G, Vadaketh J, Pandit R. A rare case of levetiracetam-induced refractory hypokalemia. <i>Cureus</i>. 2022;14(4):e23817. doi:10.7759/cureus.23817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35530900/pubmed" id="35530900" target="_blank">35530900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12697136">
<a name="12697136"></a>Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. <i>Epilepsy Behav</i>. 2003;4(2):124-132. doi: 10.1016/s1525-5050(03)00005-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/12697136/pubmed" id="12697136" target="_blank">12697136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29026345">
<a name="29026345"></a>De Luca F, Losappio LM, Mirone C, et al. Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature. <i>Clin Mol Allergy</i>. 2017;15:16. doi: 10.1186/s12948-017-0072-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29026345/pubmed" id="29026345" target="_blank">29026345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.2018">
<a name="Drislane.2018"></a>Drislane F. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23324778">
<a name="23324778"></a>Duong TA, Haddad C, Valeyrie-Allanore L, Sbidian E, Chosidow O, Wolkenstein P. Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases. <i>JAMA Dermatol</i>. 2013;149(1):113-115. doi: 10.1001/2013.jamadermatol.266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23324778/pubmed" id="23324778" target="_blank">23324778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24397826">
<a name="24397826"></a>Eleni K. Dress syndrome induced by levetiracetam. <i>J Eur Acad Dermatol Venereol</i>. 2015;29(2):377-378. doi: 10.1111/jdv.12346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24397826/pubmed" id="24397826" target="_blank">24397826</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Elepsia XR (levetiracetam) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28275024">
<a name="28275024"></a>Fagan A, Fuld J, Soon E. Levetiracetam-induced eosinophilic pneumonia. <i>BMJ Case Rep</i>. 2017;2017:bcr2016219121. doi:10.1136/bcr-2016-219121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28275024/pubmed" id="28275024" target="_blank">28275024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37123333">
<a name="37123333"></a>Faghihjouibari M, Khadivi M, Rouhani R, et al. Comparison of efficacy and safety of levetiracetam versus phenytoin for post-craniotomy seizure prophylaxis. <i>Med J Islam Repub Iran</i>. 2023;37:7. doi:10.47176/mjiri.37.7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/37123333/pubmed" id="37123333" target="_blank">37123333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28553374">
<a name="28553374"></a>Falsaperla R, Vitaliti G, Mauceri L, et al. Levetiracetam in neonatal seizures as first-line treatment: a prospective study. <i>J Pediatr Neurosci</i>. 2017;12(1):24-28. doi:10.4103/jpn.JPN_172_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28553374/pubmed" id="28553374" target="_blank">28553374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15978308">
<a name="15978308"></a>Fay MA, Sheth RD, Gidal BE. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. <i>Clin Ther</i>. 2005;27(5):594-598. doi: 10.1016/j.clinthera.2005.05.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/15978308/pubmed" id="15978308" target="_blank">15978308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22738092">
<a name="22738092"></a>Fuller KL, Wang YY, Cook MJ, Murphy MA, D'Souza WJ. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. <i>Epilepsia</i>. 2013;54(1):45-57. doi: 10.1111/j.1528-1167.2012.03563.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22738092/pubmed" id="22738092" target="_blank">22738092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20133173">
<a name="20133173"></a>Fürwentsches A, Bussmann C, Ramantani G, et al. Levetiracetam in the Treatment of Neonatal Seizures: A Pilot Study. <i>Seizure.</i> 2010;19(3):185-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/20133173/pubmed" id="20133173" target="_blank">20133173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17095892">
<a name="17095892"></a>Gatto EM, Roca CU, Etcheverry JL, Fadel D. Levetiracetam-induced Parkinsonism in a Huntington disease patient. <i>Clin Neuropharmacol</i>. 2006;29(6):303-304. doi:10.1097/01.WNF.0000240946.51994.DF<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17095892/pubmed" id="17095892" target="_blank">17095892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27927707">
<a name="27927707"></a>García Carretero R, Romero Brugera M, Olid-Velilla M, Salamanca-Ramirez I. Pancytopenia associated with levetiracetam in an epileptic woman. <i>BMJ Case Rep</i>. 2016;2016:bcr2016217407. doi:10.1136/bcr-2016-217407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27927707/pubmed" id="27927707" target="_blank">27927707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17825078">
<a name="17825078"></a>Gelisse P, Juntas-Morales R, Genton P, et al. Dramatic weight loss with levetiracetam. <i>Epilepsia</i>. 2008;49(2):308-315. doi:10.1111/j.1528-1167.2007.01273.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17825078/pubmed" id="17825078" target="_blank">17825078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26702269">
<a name="26702269"></a>Gencler OS, Gencler B, Altunel CT, Arslan N. Levetiracetam induced psoriasiform drug eruption: a rare case report. <i>Saudi Pharm J</i>. 2015;23(6):720-722. doi:10.1016/j.jsps.2015.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26702269/pubmed" id="26702269" target="_blank">26702269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17442002">
<a name="17442002"></a>Glauser TA, Mitchell WG, Weinstock A, et al. Pharmacokinetics of Levetiracetam in Infants and Young Children With Epilepsy. <i>Epilepsia.</i> 2007;48(6):1117-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17442002/pubmed" id="17442002" target="_blank">17442002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29899787">
<a name="29899787"></a>Gohil JR, Agarwal TS. Levetiracetam adverse drug reaction: Pancytopenia. <i>J Pediatr Neurosci</i>. 2018;13(1):116-117. doi:10.4103/JPN.JPN_139_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29899787/pubmed" id="29899787" target="_blank">29899787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22764327">
<a name="22764327"></a>Gómez-Zorrilla S, Ferraz AV, Pedrós C, Lemus M, Peña C. Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome. <i>Ann Pharmacother</i>. 2012;46(7-8):e20. doi: 10.1345/aph.1R084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22764327/pubmed" id="22764327" target="_blank">22764327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31477643">
<a name="31477643"></a>Gowda VK, Romana A, Shivanna NH, Benakappa N, Benakappa A. Levetiracetam versus phenobarbitone in neonatal seizures - a randomized controlled trial. <i>Indian Pediatr</i>. 2019;56(8):643-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31477643/pubmed" id="31477643" target="_blank">31477643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17368928">
<a name="17368928"></a>Grosso S, Cordelli DM, Franzoni E, et al. Efficacy and Safety of Levetiracetam in Infants and Young Children With Refractory Epilepsy. <i>Seizure.</i> 2007;16(4):345-350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17368928/pubmed" id="17368928" target="_blank">17368928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29114859">
<a name="29114859"></a>Guilfoyle SM, Follansbee-Junger K, Smith AW, et al. Antiepileptic drug behavioral side effects and baseline hyperactivity in children and adolescents with new onset epilepsy. <i>Epilepsia</i>. 2018;59(1):146-154. doi: 10.1111/epi.13946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29114859/pubmed" id="29114859" target="_blank">29114859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28458437">
<a name="28458437"></a>Gupta M. Levetiracetam-induced leukocytoclastic vasculitis. <i>Indian J Pharmacol</i>. 2017;49(1):124-126. doi:10.4103/0253-7613.201020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28458437/pubmed" id="28458437" target="_blank">28458437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34164804">
<a name="34164804"></a>Haller JT, Bonnin S, Radosevich J. Rapid administration of undiluted intravenous levetiracetam. <i>Epilepsia.</i> 2021;62(8):1865-1870. doi:10.1111/epi.1696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/34164804/pubmed" id="34164804" target="_blank">34164804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29636029">
<a name="29636029"></a>Han JY, Moon CJ, Youn YA, Sung IK, Lee IG. Efficacy of levetiracetam for neonatal seizures in preterm infants. <i>BMC Pediatr</i>. 2018;18(1):131. doi:10.1186/s12887-018-1103-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29636029/pubmed" id="29636029" target="_blank">29636029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30581496">
<a name="30581496"></a>Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. <i>Behav Neurol</i>. 2018;2018:2064027. doi: 10.1155/2018/2064027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30581496/pubmed" id="30581496" target="_blank">30581496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36936131">
<a name="36936131"></a>Hegazy Y, Axley P, Lee G, Gray M. Levetiracetam liver injury: a benign antiepileptic agent?. <i>ACG Case Rep J</i>. 2023;10(3):e01003. doi:10.14309/crj.0000000000001003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/36936131/pubmed" id="36936131" target="_blank">36936131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22551726">
<a name="22551726"></a>Hernández-Díaz S, Smith CR, Shen A, et al. Comparative Safety of Antiepileptic Drugs During Pregnancy. <i>Neurology.</i> 2012;8(21):1692-1699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22551726/pubmed" id="22551726" target="_blank">22551726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32113977">
<a name="32113977"></a>Hernández-Mitre MP, Medellín-Garibay SE, Rodríguez-Leyva I, et al. Population pharmacokinetics and dosing recommendations of levetiracetam in adult and elderly patients with epilepsy. <i>J Pharm Sci.</i> 2020;109(6):2070-2078. doi:10.1016/j.xphs.2020.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/32113977/pubmed" id="32113977" target="_blank">32113977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017 [published correction appears in <i>Pharmacopsychiatry</i>. 2018;51(1-02):e1]. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi: 10.1055/s-0043-116492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32950862">
<a name="32950862"></a>Hnaini M, Darwich M, Koleilat N, et al. High-dose levetiracetam for neonatal seizures: a retrospective review. <i>Seizure</i>. 2020;82:7-11. doi:10.1016/j.seizure.2020.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/32950862/pubmed" id="32950862" target="_blank">32950862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37212182">
<a name="37212182"></a>Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2023;54(7):e314-e370. doi:10.1161/STR.00000000000004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/37212182/pubmed" id="37212182" target="_blank">37212182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19520278">
<a name="19520278"></a>Hurwitz KA, Ingulli EG, Krous HF. Levetiracetam induced interstitial nephritis and renal failure. <i>Pediatr Neurol</i>. 2009;41(1):57-58. doi:10.1016/j.pediatrneurol.2009.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19520278/pubmed" id="19520278" target="_blank">19520278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25511789">
<a name="25511789"></a>Iuchi T, Kuwabara K, Matsumoto M, Kawasaki K, Hasegawa Y, Sakaida T. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. <i>J Neurol Neurosurg Psychiatry</i>. 2015;86(10):1158-1162. doi: 10.1136/jnnp-2014-308584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/25511789/pubmed" id="25511789" target="_blank">25511789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33877137">
<a name="33877137"></a>Jadhav P, Kulkarni T, Jadhav J, Desai S, Baviskar R. Levetiracetam-induced systemic lupus erythematosus. <i>J R Coll Physicians Edinb</i>. 2021;51(1):58-60. doi:10.4997/JRCPE.2021.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/33877137/pubmed" id="33877137" target="_blank">33877137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35848684">
<a name="35848684"></a>James J, Jose J, Gafoor VA. Levetiracetam-induced gingival hyperplasia. <i>J Postgrad Med</i>. 2022;68(3):168-169. doi:10.4103/jpgm.jpgm_1059_21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35848684/pubmed" id="35848684" target="_blank">35848684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30984385">
<a name="30984385"></a>Jayashankar S, Munakomi S, Sayeerajan V, et al. Case report: Levetiracetam causing acute liver failure complicating post-operative management in a neurosurgical patient. <i>F1000Res</i>. 2019;8:187. doi:10.12688/f1000research.18198.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30984385/pubmed" id="30984385" target="_blank">30984385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jirsch.2020">
<a name="Jirsch.2020"></a>Jirsch J, Hirsch LJ. Nonconvulsive status epilepticus: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15857447">
<a name="15857447"></a>Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. <i>Epilepsia</i>. 2005;46(5):775-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/15857447/pubmed" id="15857447" target="_blank">15857447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25259954">
<a name="25259954"></a>Jones RT, Evans W, Mersfelder TL, Kavanaugh K. Rare red rashes: A case report of levetiracetam-induced cutaneous reaction and review of the literature. <i>Am J Ther</i>. 2016;23(3):e944-946. doi: 10.1097/MJT.0000000000000105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/25259954/pubmed" id="25259954" target="_blank">25259954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29753294">
<a name="29753294"></a>Josephson CB, Engbers JDT, Jette N, et al. Prescription trends and psychiatric symptoms following first receipt of one of seven common antiepileptic drugs in general practice. <i>Epilepsy Behav.</i> 2018;84:49-55. doi: 10.1016/j.yebeh.2018.04.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29753294/pubmed" id="29753294" target="_blank">29753294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32223067">
<a name="32223067"></a>Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A practice-based, clinical pharmacokinetic study to inform levetiracetam dosing in critically ill patients undergoing continuous venovenous hemofiltration (PADRE-01). <i>Clin Transl Sci.</i> 2020;13(5):950-959. doi:10.1111/cts.12782<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/32223067/pubmed" id="32223067" target="_blank">32223067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29898971">
<a name="29898971"></a>Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. <i>Neurology</i>. 2018;91(2):74-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29898971/pubmed" id="29898971" target="_blank">29898971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15773258">
<a name="15773258"></a>Kapoor P, McCabe P, Kothari MJ. Levetiracetam induced polyneuropathy: a case report. <i>Electromyogr Clin Neurophysiol</i>. 2005;45(1):15-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/15773258/pubmed" id="15773258" target="_blank">15773258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774955">
<a name="31774955"></a>Kapur J, Elm J, Chamberlain JM, et al; NETT and PECARN Investigators. Randomized trial of three anticonvulsant medications for status epilepticus. <i>N Engl J Med</i>. 2019;381(22):2103-2113. doi: 10.1056/NEJMoa1905795.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31774955/pubmed" id="31774955" target="_blank">31774955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24919470">
<a name="24919470"></a>Karamchandani RR, Fletcher JJ, Pandey AS, Rajajee V. Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. <i>J Clin Neurosci</i>. 2014;21(9):1507-1513. doi:10.1016/j.jocn.2014.03.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24919470/pubmed" id="24919470" target="_blank">24919470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34750046">
<a name="34750046"></a>Keene JC, Morgan LA, Abend NS, et al. Treatment of neonatal seizures: comparison of treatment pathways from 11 neonatal intensive care units. <i>Pediatr Neurol</i>. 2022b;128:67-74. doi:10.1016/j.pediatrneurol.2021.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/34750046/pubmed" id="34750046" target="_blank">34750046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35350164">
<a name="35350164"></a>Keene JC, Wainwright M, Morgan LA, et al. Retrospective evaluation of first-line levetiracetam use for neonatal seizures after congenital heart defect repair with or without extracorporeal membrane oxygenation. <i>J Pediatr Pharmacol Ther</i>. 2022a;27(3):254-262. doi:10.5863/1551-6776-27.3.254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35350164/pubmed" id="35350164" target="_blank">35350164</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Keppra (levetiracetam) injection [prescribing information]. Smyrna, GA: UCB Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keppra.2">
<a name="Keppra.2"></a>Keppra (levetiracetam) tablets and oral solution [prescribing information]. Smyrna, GA: UCB Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keppra.2">
<a name="Keppra.2"></a>Keppra (levetiracetam) tablets and oral solution [prescribing information]. Smyrna, GA: UCB Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KeppraXR.1">
<a name="KeppraXR.1"></a>Keppra XR (levetiracetam) [prescribing information]. Smyrna, GA: UCB Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KeppraXR.1">
<a name="KeppraXR.1"></a>Keppra XR (levetiracetam) [prescribing information]. Smyrna, GA: UCB Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21397167">
<a name="21397167"></a>Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. <i>Pediatr Neurol</i>. 2011;44(4):265-269. doi:10.1016/j.pediatrneurol.2010.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21397167/pubmed" id="21397167" target="_blank">21397167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23921284">
<a name="23921284"></a>Khan O, Cipriani C, Wright C, Crisp E, Kirmani B. Role of intravenous levetiracetam for acute seizure management in preterm neonates. <i>Pediatr Neurol</i>. 2013;49(5):340-343. doi:10.1016/j.pediatrneurol.2013.05.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23921284/pubmed" id="23921284" target="_blank">23921284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997613">
<a name="31997613"></a>Kim HK, Kim DY, Bae EK, Kim DW. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008-2017. <i>J Korean Med Sci</i>. 2020;35(4):e17. doi: 10.3346/jkms.2020.35.e17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31997613/pubmed" id="31997613" target="_blank">31997613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28202425">
<a name="28202425"></a>Kim J, Shin JW. Levetiracetam-induced thrombocytopenia in a patient with status epilepticus. <i>Epileptic Disord</i>. 2017;19(1):104-108. doi:10.1684/epd.2017.0889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28202425/pubmed" id="28202425" target="_blank">28202425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30829890">
<a name="30829890"></a>Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation Guidelines [published correction appears in <i>Pediatr Crit Care Med</i>. 2019;20(4):404]. <i>Pediatr Crit Care Med</i>. 2019;20(3S)(suppl 1):S1-S82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30829890/pubmed" id="30829890" target="_blank">30829890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24262344">
<a name="24262344"></a>Koklu E, Ariguloglu EA, Koklu S. Levetiracetam-induced anaphylaxis in a neonate. <i>Pediatr Neurol</i>. 2014;50(2):192-194. doi:10.1016/j.pediatrneurol.2013.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24262344/pubmed" id="24262344" target="_blank">24262344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11879376">
<a name="11879376"></a>Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam Psychosis in Children With Epilepsy. <i>Epilepsia.</i> 2001;42(12):1611-1613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/11879376/pubmed" id="11879376" target="_blank">11879376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18505995">
<a name="18505995"></a>Koubeissi MZ, Amina S, Pita I, Bergey GK, Werz MA. Tolerability and efficacy of oral loading of levetiracetam. <i>Neurology.</i> 2008;70(22, pt 2):2166-2170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18505995/pubmed" id="18505995" target="_blank">18505995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kramer.1">
<a name="Kramer.1"></a>Kramer G, Hosli I, Glanzmann R et al. Levetiracetam accumulation in human breast milk. <i>Epilepsia</i>. 2002;43 (Suppl 7):105.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30004278">
<a name="30004278"></a>Lee CH, Koo HW, Han SR, Choi CY, Sohn MJ, Lee CH. Phenytoin versus levetiracetam as prophylaxis for postcraniotomy seizure in patients with no history of seizures: systematic review and meta-analysis. <i>J Neurosurg</i>. 2019;130(6):1-8. doi:10.3171/2018.4.JNS1891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30004278/pubmed" id="30004278" target="_blank">30004278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23451808">
<a name="23451808"></a>Lee YY, Ko JH, Chung WH. Acute generalized exanthematous pustulosis induced by levetiracetam. <i>Int J Dermatol</i>. 2014;53(1):e5-6. doi: 10.1111/j.1365-4632.2012.05549.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23451808/pubmed" id="23451808" target="_blank">23451808</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Levetiracetam in Sodium Chloride Injection [prescribing information]. Paramus, NJ: WG Critical Care, LLC; April 2021.</div>
</li>
<li>
<div class="reference">
                  Levetiracetam injection, for intravenous use [prescribing information]. Lake Forest, IL: Hospira; July 2021.</div>
</li>
<li>
<div class="reference">
                  Levetiracetam injection, for intravenous use [prescribing information]. Lake Forest, IL: Hospira; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28189379">
<a name="28189379"></a>Levy ZD, Slowey M, Schulder M. Acute generalized exanthematous pustulosis secondary to levetiracetam and valproic acid use.<i> Am J Emerg Med</i>. 2017;35(7):1036.e1-1036.e2. doi: 10.1016/j.ajem.2017.02.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28189379/pubmed" id="28189379" target="_blank">28189379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19362602">
<a name="19362602"></a>López-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. <i>Epilepsy Behav</i>. 2009;15(3):372-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19362602/pubmed" id="19362602" target="_blank">19362602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28629473">
<a name="28629473"></a>Lyttle MD, Gamble C, Messahel S, et al. Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial. <i>Trials</i>. 2017;18(1):283. doi:10.1186/s13063-017-2010-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28629473/pubmed" id="28629473" target="_blank">28629473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24051577">
<a name="24051577"></a>Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. <i>J Perinatol</i>. 2013;33(11):841-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24051577/pubmed" id="24051577" target="_blank">24051577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16159526">
<a name="16159526"></a>Mandelbaum DE, Bunch M, Kugler SL, et al. Efficacy of Levetiracetam at 12 Months in Children Classified By Seizure Type, Cognitive Status, and Previous Anticonvulsant Drug Use. <i>J Child Neurol.</i> 2005;20(7):590-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16159526/pubmed" id="16159526" target="_blank">16159526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37492848">
<a name="37492848"></a>Mann H, Kusayev J, Pandey S, Aryal B, Solaimanzadeh I. A rare presentation of levetiracetam-induced torsades de pointes. <i>Cureus</i>. 2023;15(6):e40866. doi:10.7759/cureus.40866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/37492848/pubmed" id="37492848" target="_blank">37492848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23303847">
<a name="23303847"></a>Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. <i>Neurology</i>. 2013;80(4):400-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23303847/pubmed" id="23303847" target="_blank">23303847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller GS. Pyridoxine Ameliorates Adverse Behavioral Effects of Levetiracetam in Children. <i>Epilepsia.</i> 2002;43(suppl 7):S62.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21586715">
<a name="21586715"></a>Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. <i>JAMA</i>. 2011;305(19):1996-2002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21586715/pubmed" id="21586715" target="_blank">21586715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30919301">
<a name="30919301"></a>Morgan O, Medenwald B. Safety and tolerability of rapid administration undiluted levetiracetam. <i>Neurocrit Care</i>. 2020;32(1):131-134. doi:10.1007/s12028-019-00708-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30919301/pubmed" id="30919301" target="_blank">30919301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14741183">
<a name="14741183"></a>Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. <i>Seizure</i>. 2004;13(1):55-57. doi: 10.1016/s1059-1311(03)00111-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/14741183/pubmed" id="14741183" target="_blank">14741183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21492729">
<a name="21492729"></a>Murphy-Human T, Welch E, Zipfel G, Diringer MN, Dhar R. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. <i>World Neurosurg</i>. 2011;75(2):269-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21492729/pubmed" id="21492729" target="_blank">21492729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15946344">
<a name="15946344"></a>Nasrallah K, Silver B. Hyponatremia associated with repeated use of levetiracetam. <i>Epilepsia</i>. 2005;46(6):972-973. doi:10.1111/j.1528-1167.2005.64004.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/15946344/pubmed" id="15946344" target="_blank">15946344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Clinical Guideline Centre. Diagnoiss and management of drug allergy in adults, children and young people. <i>Drug Allergy</i>. 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17690072">
<a name="17690072"></a>Newsome SD, Xue LY, Jennings T, Castaneda GY. Levetiracetam-induced diffuse interstitial lung disease. <i>J Child Neurol</i>. 2007;22(5):628-630. doi:10.1177/0883073807302602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17690072/pubmed" id="17690072" target="_blank">17690072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18285535">
<a name="18285535"></a>Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. <i>Neurology</i>. 2008;70(8):607-616. doi: 10.1212/01.wnl.0000297512.18364.40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18285535/pubmed" id="18285535" target="_blank">18285535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35804217">
<a name="35804217"></a>Nonaka M, Neshige S, Maruyama H. Levetiracetam-induced myoclonus following recovery from non-convulsive status epilepticus in an elderly woman. <i>Intern Emerg Med</i>. 2022;17(6):1829-1830. doi:10.1007/s11739-022-03040-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35804217/pubmed" id="35804217" target="_blank">35804217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26893076">
<a name="26893076"></a>Oh SJ, Kwon HI, Moon SH, Ro YS, Ko JY. Toxic epidermal necrolysis with isolated neutropenia related to the use of levetiracetam. <i>J Dermatol</i>. 2016;43(8):969-971. doi: 10.1111/1346-8138.13309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26893076/pubmed" id="26893076" target="_blank">26893076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16182573">
<a name="16182573"></a>Opp J, Tuxhorn I, May T, et al. Levetiracetam in Children With Refractory Epilepsy: A Multicenter Open Label Study in Germany. <i>Seizure.</i> 2005;14(7):476-484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16182573/pubmed" id="16182573" target="_blank">16182573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29313528">
<a name="29313528"></a>Ozdemir H, Sumer S, Karabagli H, Akdemir G, Caliskaner AZ, Artac H. B cell aplasia and hypogammaglobulinemia associated with levetiracetam. <i>Ann Saudi Med</i>. 2018;38(1):65-68. doi:10.5144/0256-4947.2018.09.01.1430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29313528/pubmed" id="29313528" target="_blank">29313528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paisansathan.1">
<a name="Paisansathan.1"></a>Paisansathan C, Ozcan MS. Anesthesia for craniotomy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23911354">
<a name="23911354"></a>Paret N, Gouraud A, Bernard N, et al. Long-term follow-up of infants exposed to levetiracetam during breastfeeding: Comparison to a control group. <i>Birth Defects Res A Clin Mol Teratol</i>. 2014;100:537-538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23911354/pubmed" id="23911354" target="_blank">23911354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31332981">
<a name="31332981"></a>Park CS, Kang DY, Kang MG, et al; Korean Registry of Severe Cutaneous Adverse Reactions Consortium. Severe cutaneous adverse reactions to antiepileptic drugs: A nationwide registry-based study in Korea. <i>Allergy Asthma Immunol Res</i>. 2019;11(5):709-722. doi: 10.4168/aair.2019.11.5.709.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31332981/pubmed" id="31332981" target="_blank">31332981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi: 10.1097/FTD.0000000000000546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23876024">
<a name="23876024"></a>Pearl PL, McCarter R, McGavin CL, et al. Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy. <i>Epilepsia</i>. 2013;54(9):e135-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23876024/pubmed" id="23876024" target="_blank">23876024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11879369">
<a name="11879369"></a>Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic Study of Levetiracetam in Children. <i>Epilepsia</i>, 2001;42(12):1574-1579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/11879369/pubmed" id="11879369" target="_blank">11879369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19317886">
<a name="19317886"></a>Peltola J, Coetzee C, Jiménez F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. <i>Epilepsia</i>. 2009;50(3):406-414. doi:10.1111/j.1528-1167.2008.01817.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19317886/pubmed" id="19317886" target="_blank">19317886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17430408">
<a name="17430408"></a>Perry MS, Benatar M. Efficacy and Tolerability of Levetiracetam in Children Younger Than 4 Years: A Retrospective Review. <i>Epilepsia.</i> 2007;48(6):1123-1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17430408/pubmed" id="17430408" target="_blank">17430408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37367730">
<a name="37367730"></a>Pitton Rissardo J, Fornari Caprara AL, Casares M, Skinner HJ, Hamid U. Antiseizure medication-induced alopecia: a literature review. <i>Medicines (Basel)</i>. 2023;10(6):35. doi:10.3390/medicines10060035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/37367730/pubmed" id="37367730" target="_blank">37367730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26945547">
<a name="26945547"></a>Pourzitaki C, Tsaousi G, Apostolidou E, Karakoulas K, Kouvelas D, Amaniti E. Efficacy and safety of prophylactic levetiracetam in supratentorial brain tumour surgery: a systematic review and meta-analysis. <i>Br J Clin Pharmacol</i>. 2016;82(1):315-325. doi: 10.1111/bcp.12926.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26945547/pubmed" id="26945547" target="_blank">26945547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29744119">
<a name="29744119"></a>Rachamallu V, Song MM, Reed JM, Aligeti M. Levetiracetam-induced transaminitis in a young male with traumatic brain injury. <i>Oxf Med Case Reports</i>. 2017;2017(11):omx067. doi:10.1093/omcr/omx067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/29744119/pubmed" id="29744119" target="_blank">29744119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16886975">
<a name="16886975"></a>Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. <i>Epilepsia</i>. 2006a;47(7):1128-1135. doi: 10.1111/j.1528-1167.2006.00586.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16886975/pubmed" id="16886975" target="_blank">16886975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16861095">
<a name="16861095"></a>Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. <i>Clin Ther</i>. 2006b;28(5):734-744. doi: 10.1016/j.clinthera.2006.05.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16861095/pubmed" id="16861095" target="_blank">16861095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21094062">
<a name="21094062"></a>Ramantani G, Ikonomidou C, Walter B, et al. Levetiracetam: Safety and Efficacy in Neonatal Seizures. <i>Eur J Paediatr Neurol.</i> 2011;15(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21094062/pubmed" id="21094062" target="_blank">21094062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30296665">
<a name="30296665"></a>Rao LM, Hussain SA, Zaki T, et al. A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic-ischemic encephalopathy. <i>Epilepsy Behav</i>. 2018;88:212-217. doi:10.1016/j.yebeh.2018.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30296665/pubmed" id="30296665" target="_blank">30296665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235418">
<a name="34235418"></a>Rogalewski A, Zuhorn F, Wilkens L, Krüger M, Klingebiel R, Schäbitz WR. Severe drug-induced liver injury caused by levetiracetam - a case report and review of the literature. <i>Epilepsy Behav Rep</i>. 2021;16:100464. doi:10.1016/j.ebr.2021.100464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/34235418/pubmed" id="34235418" target="_blank">34235418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19264451">
<a name="19264451"></a>Rouits E, Burton I, Guénolé E, Troenaru MM, Stockis A, Sargentini-Maier ML. Pharmacokinetics of levetiracetam XR 500mg tablets. <i>Epilepsy Res</i>. 2009;84(2-3):224-231. doi:10.1016/j.eplepsyres.2009.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19264451/pubmed" id="19264451" target="_blank">19264451</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Roweepra (levetiracetam) [prescribing information]. Naperville, IL: OWP Pharmaceuticals Inc; February 2022.</div>
</li>
<li>
<div class="reference">
                  Roweepra (levetiracetam) [prescribing information]. Naperville, IL: OWP Pharmaceuticals Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37575737">
<a name="37575737"></a>Saito S, Iijima M, Ikeguchi R, Ishizuka K, Kitagawa K. Four cases of suspected levetiracetam-induced asymptomatic rhabdomyolysis. <i>Cureus</i>. 2023;15(7):e41666. doi:10.7759/cureus.41666<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/37575737/pubmed" id="37575737" target="_blank">37575737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35146103">
<a name="35146103"></a>Santaliz-Ruiz LEI, Blanco-Cintron ME, Caro-Muñiz AP, Villa J, Martin-Garcia RF. Levetiracetam-induced bullous pemphigoid in a young adult woman. <i>JAAD Case Rep</i>. 2022;21:56-58. doi:10.1016/j.jdcr.2021.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35146103/pubmed" id="35146103" target="_blank">35146103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi: 10.1186/s13601-015-0073-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22495532">
<a name="22495532"></a>Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. <i>Pediatr Res</i>. 2012;72(1):43-49. doi:10.1038/pr.2012.51<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22495532/pubmed" id="22495532" target="_blank">22495532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32385134">
<a name="32385134"></a>Sharpe C, Reiner GE, Davis SL, et al. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. <i>Pediatrics</i>. 2020;145(6):e20193182. doi:10.1542/peds.2019-3182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/32385134/pubmed" id="32385134" target="_blank">32385134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608315">
<a name="17608315"></a>Shoemaker MT, Rotenberg JS. Levetiracetam for the Treatment of Neonatal Seizures. <i>J Child Neurol.</i> 2007;22(1):95-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17608315/pubmed" id="17608315" target="_blank">17608315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18639748">
<a name="18639748"></a>Silverstein FS, Ferriero DM. Off-Label Use of Antiepileptic Drugs for the Treatment of Neonatal Seizures. <i>Pediatr Neurol.</i> 2008;39(2):77-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18639748/pubmed" id="18639748" target="_blank">18639748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27546759">
<a name="27546759"></a>Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. <i>J Crit Care</i>. 2016;36:116-124. doi:10.1016/j.jcrc.2016.06.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27546759/pubmed" id="27546759" target="_blank">27546759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30237016">
<a name="30237016"></a>Sourbron J, Chan H, Wammes-van der Heijden EA, et al. Review on the relevance of therapeutic drug monitoring of levetiracetam. <i>Seizure</i>. 2018;62:131-135. doi: 10.1016/j.seizure.2018.09.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/30237016/pubmed" id="30237016" target="_blank">30237016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21950640">
<a name="21950640"></a>Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. <i>Pharmacotherapy</i>. 2011;31(10):934-941. doi:10.1592/phco.31.10.934.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21950640/pubmed" id="21950640" target="_blank">21950640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spritam.1">
<a name="Spritam.1"></a>Spritam (levetiracetam) [prescribing information]. Blue Ash, OH: Aprecia Pharmaceuticals LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35121708">
<a name="35121708"></a>Stoppa A, Anmella G, Delgado L, Vallès V, Pintor L. A manic episode with psychotic features associated with levetiracetam: a case report, a proposal of prodromal and discriminative symptoms and a possible pathophysiological mechanism. <i>J Clin Psychopharmacol</i>. 2022;42(3):316-317. doi:10.1097/JCP.0000000000001525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35121708/pubmed" id="35121708" target="_blank">35121708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16078205">
<a name="16078205"></a>Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. <i>Mov Disord</i>. 2005;20(12):1610-1614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16078205/pubmed" id="16078205" target="_blank">16078205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35089342">
<a name="35089342"></a>Sun W, He Y, Li Z, Wang C. Analysis of the clinical characteristics of the liver injury induced by levetiracetam. <i>J Pharm Pharmacol</i>. 2022;74(3):409-414. doi:10.1093/jpp/rgab181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35089342/pubmed" id="35089342" target="_blank">35089342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19898966">
<a name="19898966"></a>Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. <i>Neurocrit Care</i>. 2010;12(2):165-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19898966/pubmed" id="19898966" target="_blank">19898966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26045109">
<a name="26045109"></a>Taberner Bonastre MT, Peralta Muñoz S, Boza FM, Gumà I Padró J. Neutropenia secondary to exposure to levetiracetam. <i>Tumori</i>. 2015;101(5):e145-146. doi:10.5301/tj.5000312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/26045109/pubmed" id="26045109" target="_blank">26045109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36439615">
<a name="36439615"></a>Tahir H, Ayyaz F, Ekwegh U. Visual and auditory hallucinations: an uncommon side effect of levetiracetam in an elderly patient. <i>Cureus</i>. 2022;14(10):e30668. doi:10.7759/cureus.30668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/36439615/pubmed" id="36439615" target="_blank">36439615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28478592">
<a name="28478592"></a>Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R. Antiepileptic drug treatment in community-dwelling older patients with epilepsy: a retrospective observational study of old- versus new-generation antiepileptic drugs.<i> Drugs Aging</i>. 2017;34(6):479-487. doi: 10.1007/s40266-017-0465-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28478592/pubmed" id="28478592" target="_blank">28478592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32162678">
<a name="32162678"></a>Thibault C, Naim MY, Abend NS, et al. A retrospective comparison of phenobarbital and levetiracetam for the treatment of seizures following cardiac surgery in neonates. <i>Epilepsia</i>. 2020;61(4):627-635. doi:10.1111/epi.16469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/32162678/pubmed" id="32162678" target="_blank">32162678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17381438">
<a name="17381438"></a>Tomson T, Palm R, Källén K, et al. Pharmacokinetics of Levetiracetam During Pregnancy, Delivery, in the Neonatal Period, and Lactation. <i>Epilepsia.</i> 2007;48(6):1111-1116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17381438/pubmed" id="17381438" target="_blank">17381438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22933814">
<a name="22933814"></a>Trinka E, Marson AG, Van Paesschen W, et al; KOMET Study Group. KOMET: an unblinded, randomized, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. <i>J Neurol Neurosurg Psychiatry</i>. 2013;84(10):1138-1147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22933814/pubmed" id="22933814" target="_blank">22933814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18294118">
<a name="18294118"></a>Vaisleib II, Neft RA. Rapid dosage titration of levetiracetam in children. <i>Pharmacotherapy.</i> 2008;28(3):393-396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18294118/pubmed" id="18294118" target="_blank">18294118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22104350">
<a name="22104350"></a>Vajda FJ, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs--the Australian experience. <i>J Clin Neurosci</i>. 2012;19(1):57-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22104350/pubmed" id="22104350" target="_blank">22104350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28446744">
<a name="28446744"></a>Van Matre ET, Mueller SW, Fish DN, et al. Levetiracetam pharmacokinetics in a patient with intracranial hemorrhage undergoing continuous veno-venous hemofiltration. <i>Am J Case Rep</i>. 2017;18:458-462. doi:10.12659/ajcr.902709.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/28446744/pubmed" id="28446744" target="_blank">28446744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27872177">
<a name="27872177"></a>Venkatesan C, Young S, Schapiro M, Thomas C. Levetiracetam for the treatment of seizures in neonatal hypoxic ischemic encephalopathy. <i>J Child Neurol</i>. 2017;32(2):210-214. doi:10.1177/0883073816678102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27872177/pubmed" id="27872177" target="_blank">27872177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24339623">
<a name="24339623"></a>Verma R, Lalla R, Patil TB. Levetiracetam induced encephalopathy in a patient with normal renal function: an unusual clinical encounter. <i>Ann Indian Acad Neurol</i>. 2013;16(4):727-729. doi:10.4103/0972-2327.120430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24339623/pubmed" id="24339623" target="_blank">24339623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35311411">
<a name="35311411"></a>Verwoerd C, Limjoco J, Rajamanickam V, Knox A. Efficacy of levetiracetam and phenobarbital as first-line treatment for neonatal seizures. <i>J Child Neurol</i>. 2022;37(5):401-409. doi:10.1177/08830738221086107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35311411/pubmed" id="35311411" target="_blank">35311411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35758918">
<a name="35758918"></a>Vickery SB, Roach JK, Parsons C, Vickery PB. Possible levetiracetam-induced aseptic meningitis versus viral meningitis: case report and literature review. <i>Nurse Pract</i>. 2022;47(7):32-37. doi:10.1097/01.NPR.0000843216.79693.7e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35758918/pubmed" id="35758918" target="_blank">35758918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34174071">
<a name="34174071"></a>Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro Oncol.</i> 2021;23(11):1835-1844. doi:10.1093/neuonc/noab152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/34174071/pubmed" id="34174071" target="_blank">34174071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35698711">
<a name="35698711"></a>Watanabe N, Ishikawa E, Sugii N, et al. Levetiracetam versus levetiracetam plus sodium channel blockers for postoperative epileptic seizure prevention in brain tumor patients. <i>Cureus</i>. 2022;14(5):e24894. doi:10.7759/cureus.24894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/35698711/pubmed" id="35698711" target="_blank">35698711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19264738">
<a name="19264738"></a>Wheless JW, Clarke D, Hovinga CA, et al. Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study. <i>J Child Neurol.</i> 2009;24(8):946-951.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19264738/pubmed" id="19264738" target="_blank">19264738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-White.1">
<a name="White.1"></a>White R, Bradnam V; British Pharmaceutical Nutrition Group. <i> Handbook of Drug Administration via Enteral Feeding Tubes</i>. 3rd ed. London, England: Pharmaceutical Press; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27295203">
<a name="27295203"></a>Xu JC, Shen J, Shao WZ, et al. The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: a systematic review and meta-analysis. <i>Brain Inj</i>. 2016;30(9):1054-1061. doi:10.3109/02699052.2016.1170882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27295203/pubmed" id="27295203" target="_blank">27295203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25312351">
<a name="25312351"></a>Yamamoto J, Toublanc N, Kumagai Y, Stockis A. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. <i>Clin Drug Investig</i>. 2014;34(11):819–828. doi:10.1007/s40261-014-0237-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/25312351/pubmed" id="25312351" target="_blank">25312351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27395404">
<a name="27395404"></a>Yang Y, Zheng F, Xu X, Wang X. Levetiracetam versus phenytoin for seizure prophylaxis following traumatic brain injury: a systematic review and meta-analysis. <i>CNS Drugs</i>. 2016;30(8):677-688. doi: 10.1007/s40263-016-0365-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27395404/pubmed" id="27395404" target="_blank">27395404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31739779">
<a name="31739779"></a>Yim SH, Choi YH, Heo K, Cho KH. A case of dyskinesia after levetiracetam administration. <i>BMC Neurol</i>. 2019;19(1):292. doi: 10.1186/s12883-019-1519-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/31739779/pubmed" id="31739779" target="_blank">31739779</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12910 Version 792.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
